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Abstract 
Cardiotoxic effects of some old generation antiblastic drugs represent an actual problem 
in oncologic chemotherapy. In this context it seems fundamental to introduce new 
chemotherapics drawn to interact with high specificity with essential proteins in 
tumorigenesis, decreasing toxicity in health cells (targeted therapies). The life 
expectancy in chronic myeloid leukemia, acute linphoblastic leukemia and 
gastrointestinal stromal tumor patients has been improved after the introduction of a 
tyrosine kinase inhibitor, Imatinib mesylate, object of this study. 
Despite of the effectiveness of this drug, it is advancing the hypothesis that this 
molecule could have side effects on cardiovascular system. In particular, this drug could 
compromise the integrity of cardiac stem cells and their capability to replace damaged 
tissues, increasing the incidence of cardiovascular diseases. In this study we used cardiac 
stem cells: rat cardiac progenitor cells (CPCs) and human cardiac mesenchimal stem 
cells (C-MSCs). Cytotoxicity, genotoxicity, autophagy activation and oxidative stress 
induction have been evaluated. 
Doxorubicin, an old generation chemotherapy, has been used to compare in vitro 
effects induced by IM treatment with those induced by a drug with known cardiotoxic 
effects. Furthermore the effects induced by IM and Doxorubicin have been evaluated on 
their target cell lines, K562 (chronic myelogenous leukemia cell line) for IM, and MCF7 
(breast adenocarcinoma cell line) for Doxorubicin. 
Data reported in this thesis underline IM toxicity induction in target and non- target cell 
lines. Furthermore comparison with cellular response induced by Doxorubicin confirms 
the higher specificity of IM.  On the other hand it shows that an high IM concentration, 
that could result from a chronic treatment, could induce in cardiac stem cells a toxicity 
comparable with that observed in the same cell lines treated with Doxorubicin. 
Given the increasing interest in autophagy, as cellular response pathway induced by 
chemotherapic treatment, assays have been performed to understand the role of this 
pathway in IM treated cell lines. Furthermore we have verified if autophagy modulation 
could decrease toxicity induced in non- target cell lines without affecting the drug 
efficacy. 
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Riassunto 
Gli effetti cardiotossici di alcuni farmaci antiblastici di vecchia generazione 
rappresentano tuttora una problema aperto nella chemioterapia oncologica. In questo 
contesto assume sempre più importanza l’introduzione sul mercato di nuovi 
chemioterapici disegnati per interagire con elevata specificità con proteine 
fondamentali per la tumorigenesi e quindi in grado di ridurre al minimo gli effetti di 
tossicità sulle cellule sane (targeted therapies). La prospettive di vita di pazienti affetti 
da leucemia mieloide cronica, leucemia linfoblastica acuta e da tumore stromale 
gastrointestinale è stata migliorata dall’introduzione di un inibitore delle tirosina chinasi 
cellulari, Imatinib mesylate, oggetto di questo studio. Nonostante l’indiscussa efficienza 
di questo farmaco, sta lentamente avanzando l’ipotesi che questa molecola possa avere 
effetti collaterali negativi sul sistema cardiocircolatorio. In particolare la possibilità che 
questo farmaco possa compromettere l’integrità delle cellule staminali e la loro capacità 
di rimpiazzare il tessuto danneggiato aumenta la probabilità di sviluppo di patologie 
cardiovascolari. Per questo motivo in questo studio sono state utilizzate cellule staminali 
di origine cardiaca: progenitori cardiaci di ratto (CPCs) e cellule staminali mesenchimali 
cardiache di origine umana  (C-MSCs). Su queste linee cellulari sono state valutate la 
citotossicità, la genotossicità,  l’attivazione del pathway autofagico e l’induzione di 
stress ossidativo. 
È stata inoltre condotta una comparazione degli effetti indotti su cellule staminali 
cardiache da IM con quelli dovuti al trattamento con un chemioterapico di vecchia 
generazione, la doxorubicina, nota per indurre tossicità cardiaca in soggetti esposti. Gli 
effetti indotti da questi due farmaci sono stati, inoltre, valutati sulle rispettive linee 
cellulari target, le K562 (linea cellulare di leucemia mieloide cronica) per IM e le MCF7 
(linea cellulare di adenocarcinoma mammario) per la doxorubicina. 
I dati riportati in questa tesi mettono in luce che il trattamento in vitro con IM può 
indurre tossicità non solo in cellule target, ma anche in linee cellulari non- target. 
Inoltre, la comparazione con la risposta cellulare indotta dal trattamento con 
Doxorubicina ha confermato la maggiore specificità d’azione di IM. Allo stesso tempo si 
è evidenziato che un’alta concentrazione di IM, come quella che potrebbe risultare da 
un trattamento cronico, può indurre nelle cellule staminali cardiache una tossicità 
comparabile con quella osservata nelle stesse cellule trattate con Doxorubicina. 
Dato il crescente interesse nei confronti del pathway autofagico, come meccanismo di 
risposta cellulare indotto in seguito a trattamento con chemioterapici, sono stati 
condotti saggi al fine di comprendere il coinvolgimento di questo pathway nella risposta 
al trattamento con IM. Si è cercato inoltre di verificare se la modulazione della risposta 
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autofagica potesse diminuire la tossicità indotta in cellule non- target senza 
compromettere l’efficacia del farmaco stesso. 
  
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
8 
 
Chemotherapy and cardiotoxicity 
 
Cardiovascular diseases and cancer represent respectively the first and second cause of 
death in industrialized countries. These two conditions may become synergistic when 
cardiovascular complications of anti-cancer therapy are considered [Prezioso et al., 
2010].  
The National Cancer Institute defines cardiotoxicity in general terms as ‘‘toxicity that 
affects the heart’’ (http://www.cancer.gov/dictionary). This definition embraces a 
variety of side effects affecting both the heart and circulation: valvular injury, 
dysrhythmias, changes in blood pressure, arterial/venous thrombosis or impairment in 
myocardial contraction or relaxation (systolic and diastolic dysfunction) [Raschi et al., 
2012]. We can distinguish two classes of cardiotoxicity: the acute or subacute one that 
occurs  during the chemotherapy treatment, and the chronic one that can be early or 
late  if the cardiac disorders appear within a year or after the end of an year of 
treatment respectively.  
Cytostatic antibiotics of the anthracycline class (daunorubicin, doxorubicin and 
epirubicin) are perhaps the most notorious chemotherapeutics with cardiac side effects; 
other agents such as cyclophosphamide, ifosfamide, cisplatin, carmustine, busulfan, 
chlormethine, mitomycin, paclitaxel, etoposide, teniposide, the vinca alkaloids, 
fluorouracil, cytarabine, amsacrine, cladribine, asparaginase, tretinoin, and pentostatin 
have also been associated with cardiotoxicity [Jain, 2000; Ryberg et al., 1998; Schimmel 
et al., 2004]. Besides the typical chemotherapeutics, targeted therapies are also 
associated with a clinically relevant cardiotoxic profile [Geiger et al., 2010].  
 
“Old fashioned” chemotherapies 
Numerous are the old generation chemotherapies that is known to induce 
cardiotoxicity. Between these 5-Fluorouracil has been described to induce ischaemia, a 
phenomenon that is attributed to coronary vasospasm, and myocarditis [Dalzell et al., 
2009]. In this categories we have to mention the family of Anthracyclines that are 
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chemotherapies belonging to antibiotic antineoplastic class. They represent the more 
effectiveness till now developed. One of their features is the broad spectrum of activity; 
they are active antineoplastic drugs able to improve survival in adult and pediatric 
patients with hematologic (like Hodgkin disease and acute leukemia) [Tilly et al., 2003] 
and solid (like breast, ovarian and hepatic cancer and sarcomas) tumors [Cadeddu 2006; 
Jones et al., 2006]. The use of anthracyclines as antineoplastic agents in the clinic is 
compromised by the risk of cardiotoxicity. It has been calculated that approximately 
10% of patients treated with doxorubicin or its derivatives will develop cardiac 
complications up to 10 years after the cessation of chemotherapy [Yanti 2012]. 
Anthracyclines possess different mechanisms of action:  
- intercalation into DNA, leading to inhibition of synthesis of macromolecules;  
- generation of free radicals, leading to DNA damage or lipid peroxidation;  
- DNA binding and alkylation;  
- DNA cross-linking;  
- interference with DNA unwinding or DNA strand separation and helicase activity;  
- direct membrane effects;  
- initiation of DNA damage via inhibition of topoisomerase II: Anthracyclines act by 
stabilizing a reaction intermediate in which DNA strands are cut and covalently linked to 
tyrosine residues of topoisomerase II, eventually impeding DNA resealing.;  
- induction of apoptosis in response to topoisomerase II inhibition [Minotti et al., 2004]. 
 
Targeted therapies 
Many of the characteristics of cancer are manifestations of abnormal changes in the 
physiology of cancer cells, like self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of programmed cell death, limitless replicative potential, 
sustained angiogenesis, and tissue invasion/metastasis. These physiological changes 
result from genetic alterations, and for any change, a different gene or group of genes 
might be involved. The biochemical events that lead to critical changes in the physiology 
of cancer cells are becoming the newest targets for anticancer therapeutics [Cattley et 
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al., 2004]. These new drugs are able to hit only specific cellular  receptors responsible of 
the tumor development and growth, without damaging healthy cells. These molecules 
are named targeted therapies and are divided in: monoclonal antibodies generally direct 
against tyrosine- kinases or their ligands, (like trastuzumab and bevacizumab);  little 
molecules targeted against specific kinases (KI) (like Imatinib and Erlotinib). 
These drugs can offer new hope to cancer patients but treatment sometimes has been 
associated with cardiovascular complications including hypertension, left ventricular 
dysfunction, and/or heart failure [Cheng et al., 2010]. We can distinguish an ‘‘on-target’’ 
and an ‘‘off-target’’ drug side effects that lead to cardiotoxicity [Raschi et al., 2012]. 
 
‘‘On-target’’ toxicity occurs when the inhibited kinases in addition to cancer progression 
are important in other organ systems including the heart and vasculature [Cheng et al., 
2010]. An example is the cardiotoxicity induced by trastuzumab, a monoclonal antibody 
used against ERBB2 receptor (HER2). HER2 is overexpressed in about 20% breast cancers 
and it is important for tumor progression. HER2 inhibition by trastuzumab increases the 
survival of patients but sometimes induces left ventricular dysfunction because HER2 is 
involved in cardiomyocytes proliferation during the development and in their survival. 
 
“Off-target” toxicity is determined by the inhibition of non target kinases or of other 
kind of enzymes that play a key role in the heart. This kind of toxicity is linked to the low 
selectivity of certain KI because of the high dimension of human kinome [Cheng et al. 
2010].  
 
Tyrosine Kinases Inhibitors and Imatinib mesylate 
Tumor sequencing projects allowed to individuate a lot of mutation in protein kinases. 
One study found that mutations in as many as 120 kinases (or ~20% of the kinome) 
could be present in individual cancers [Schwab et al., 1986; Haber et al., 2007]. 
Approximately 90 of the 518 kinases in the human kinome are tyrosine kinases (TKs). 
This has led to develop new drugs that have as target TKs (TK inhibitors [TKIs]). TKIs 
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typically compete with ATP for binding to the ATP pocket. If ATP cannot bind, 
phosphotransferase activity is blocked and downstream substrates cannot be 
phosphorylated. In the cell, ATP is present in mM concentrations but TKIs will be 
present in nanomolar to very low micromolar concentrations. Thus they have to possess 
a very high affinity for their binding site. Because the structure of the ATP pocket is 
highly conserved across the more than 500 kinases of the human genome, it is relatively 
easy to make an inhibitor that blocks a kinase of interest. On the other hand the lack of 
selectivity is the major issue of most kinase inhibitors that target the ATP pocket; the 
aspecific inhibition of non- target kinases can induce the so- called “off-target” effects 
that lead to toxicity. The relatively poor selectivity of these kind of TKI, called Type I 
inhibitors, can be addressed by targeting additional regions of the kinase [Okram et al., 
2006]. The so-called type II inhibitors bind the ATP pocket and at the same time interact 
with a site adjacent to the pocket. This allows not only an enhanced selectivity but also 
the binding to the kinase when it is in the inactive conformation. Finally, type III 
inhibitors (for example the families of MEK inhibitors including PD98059 and UO126) 
bind to regions near the ATP pocket [Ohren et al., 2004]. These regions are typically not 
highly conserved, allowing an highest selectivity. Although type III agents are more 
selective, they are a small minority of agents in development because they are more 
difficult to design and not so predictably effective.  
 
The first TKI to reach market was imatinib mesylate (Gleevec, Novartis) (Figure 1), and it 
was approved in 2001 [Sherbenou et al., 2007] . Imatinib revolutionized the treatment 
of chronic myeloid leukemia (CML). Before the introduction of imatinib, CML was fatal 
within 5 years, whereas now, ~90% of patients are alive 5 years after diagnosis. Imatinib 
is a type II inhibitor and was designed to target Bcr-Abl, which is causal in ~90% of cases 
of CML and ~20% of acute lymphocytic leukemia (ALL).  
Figure 1: Structure of Imatinib mesylate.
 
The Bcr-Abl fusion protein is created by a balanced translocation in bone marrow 
progenitor cells that creates the Philadelphia chromosome. The protein 
nonkinase domain of Bcr (a kinase of unclear
nonreceptor TK c-Abl. The Bcr
constitutive activation of the Abl kinase domain.
by activating the Ras-Raf-ERK 
the phosphatidylinositol 3-kinase (PI3K)
factors Bad and FOXO3A), and
(which induces expression of antiapoptotic 
signaling, leading CML cells into apoptosis
Imatinib was found to inhibit two additional protein kinases that are involved in a 
variety of malignancies: c-Kit, the receptor for
in gastrointestinal stromal tumors (GISTs) (a rare tumor of the upper gastrointestinal 
tract derived from cells of neuroendocrine origin) and is mutated in systemic 
mastocytosis; and platelet-derived growth factor 
such as FIP1L1-PDGFRα and ETV6
hypereosinophilic syndromes, dermatofibrosarcoma protuberans, and chronic 
myelomonocytic leukemia. Mutations and overexpression of PDGFRs pla
other cancers including GIST and glioblastoma [
 
 
 function) and the kinase domain of the 
-Abl fusion dimerizes leading to cross-phosphorylation and 
 This protein acts  suppressing
pathway (which increases antiapoptotic Bcl2 expression), 
-Akt pathway (which inhibits the proapoptotic 
 STAT5 (signal transducer and activator of transcription 5)
Bcl-x). Imatinib blocks all Bcr-
 (figure 2) [Cheng et al., 2010].  
 stem cell factor, which is overexpressed 
receptors (PDGFRs). Fusion proteins 
- PDGFRβ are involved in rare diseases including 
Bantscheff et al., 2007].  
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Figure 2: Schematic representation of Imatinib mesylate inhibition of tyrosine- kinase 
BCR-ABL . 
 
Imatinib mesylate  and cardiotoxicity 
Despite the promise of their high selectivity that accompanied the ideation of this new 
generation drug a certain degree of toxicity was detected during the treatment. In 
particular Kerkela et al. in 2006 published a report of cardiotoxicity. They analyzed  a 
case series of 10 patients who developed congestive heart failure while receiving 
Imatinib [Kerkelä et al., 2006]. Both a “on- target” and “off-  target” toxicity have been 
detected for Imatinib. IM treatment determines the inhibition of  different tyrosine 
kinases, like c-Abl and ARG (Abl-related gene or Abl2), PDGFRs, c-Kit, the Src family 
member Lck, CSF1R, Cdc2, and discoidin domain receptor (DDR) that induces alterations 
in cellular functions (Figure 3).  
 
 Figure 3: Possible targets of Imatinib mesylate and their effects.
 
In particular c-Abl inhibition causes  
response, with activation of 
phosphorilation and the activation of elF2 (
off mRNA translation and promote
to decrease the accumulation of unfolded proteins. 
mRNA coding for XBP1 (X-box binding protein), that activates the unfolded protein 
response (UPR). Alternatively IRE1 
that can promote mithocondrial membrane permeabilization and caspases activation. 
These two pathway culminate in apoptotic cell death in cardiomyocytes 
[Kerkelä et al., 2006]. 
 
induction of the endoplasmic reticulum (ER) stress 
two different kinases PERK and IRE1; PERK
eukaryotic initiation factor 2), that switch
s the translation of specific mRNA coding chaperones 
IRE1 induces the splicing of the 
activates the JNKs kinases that induce Bax release 
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(Figure 4) 
 Figure 4: Effects of Abl inhibition by Imatinib mesylate.
 
 c-kit is involved in cardiac resident stem cells differentiation (CRSC)
in cardiac stem cells bone marrow derivative migration to the lesion regions (CSC) 
[Ayach et al., 2006]. The PDGFR inhibition compromises angiogenesis in cardiac muscle 
[Chintalgattu et al., 2010]. It, in fact, seems to be important to induce angiogenesis 
during cardiac stress [Louvet et al., 2008
target kinases such as Cdc2 and DDR1 and of the oxidoreductase NQO2 which plays
protective role in the cellular response to oxida
In a study Kerkela and collaborators
observed an enhanced susceptibility to Ca
permeability transition pore and 
marked reduction in ATP concentration, and release of 
any other inciting stimulus. Thus 
rundown of energy can represent 
 
 [Li et al., 2008
].  IM toxicity is also induced by inhibition of off
tive stress (Figure 3). 
 identified mitochondria as a target of 
2+ induced by opening of the mitochondrial 
a collapse of the mitochondrial membrane potential, a 
c cytochrome in the absence of 
mitochondrial dysfunction and the consequent 
a crucial factor in the cardiotoxicity 
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2006]. IM is also known to generate reactive oxygen species (ROS) with an increase of 
oxidative stress [Blasiak et al., 2002].  Another important observation was that the 
decrease of left ventricular mass wasn’t associated to the presence of fibrotic area 
[Kerkelä et al., 2006; Leipner et al., 2008]. Usually during a damage in cardiac tissue, like 
during an ischemia, cells activate necrotic death. If stem cells can’t replace the damaged 
tissue, the organism induce an emergency mechanism that includes the activation of 
fibroblasts. They bring to the formation of a scary consisting of connective tissue that 
hasn’t the mechanic, electric and biochemical properties of the original tissue. The 
absence of fibrotic tissue induces us to exclude the possibility that IM could induce 
necrotic death in cardiomyocytes.  
These evidences make important to investigate alternative cell deaths, first of all 
autophagy. This pathway seems to assume always higher importance because of its 
fundamental role in finally differentiated cells, especially in cardiac cells [Rabinowitz et 
al., 2010]. Cardiomyocytes replacement is more complicated than in other tissue, thus 
more susceptible to stress [Srivastava et al., 2006]. These cells with a long life span, like 
neurons, undergo accumulation of cross-linked material of proteic or lipid nature that 
can compromise mitochondria and lysosomes [Grune et al., 2005; Terman et al., 2006]. 
Actively proliferating cells can reduce these accumulations during cell division, but this is 
impossible in terminally differentiated cells. In this contest autophagy appears really 
important to maintain cellular homeostasis [Terman et al., 2006].  
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Autophagy  
The term autophagy comes from the Greek words 'phagy' meaning eat, and 'auto' 
meaning self and was founded in 1963 when de Duve described the presence of single- 
or double-membrane vesicles that contain damaged parts of cytoplasm and organelles. 
Researches on this topic began in the late 1950s, but progresses in molecular studies of 
this pathway have been made only on the past 15 years. Molecular studies, started in 
the late 1990s, have revolutionized the ability to detect and genetically manipulate this 
process. Autophagy was initially identified in mammals but a significant breakthrough 
has been made when it was discovered that it is a conserved cellular pathway from 
yeast to mammals that controls degradation of proteins and organelles, and it is 
essential in cellular survival, development and homeostasis. Cytoplasmic cargo are 
sequestered inside double-membrane vesicles and delivered to the lysosomes for 
degradation. This 'self-eating' process rids the cell of intracellular misfolded or long-lived 
proteins, superfluous or damaged organelles, and invading microorganisms, but it is also 
an adaptive response to provide nutrients and energy during various stresses. Moreover 
autophagy seems to be important for human health and is involved in physiology, 
development, lifespan and a wide range of diseases, including cancer, 
neurodegeneration, immune response and microbial infection [Yang et al., 2010].  
The recent advances in the study of autophagy allowed us to understand the differences 
among three different autophagic pathways that co-exist in most mammalian cells: 
microautophagy, chaperone-mediated autophagy (CMA) and macroautophagy (Figure 
5). 
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Figure 5: Three different autophagic pathways in mammalian cells: (a) Macroautophagy, 
(b) Microautophagy, (c) Chaperone- mediated autophagy (CMA). 
 
Microautophagy 
Between the three kind of autophagy, microautophagy is the less studied and the less 
understood. Studies on microautophagy have been focused on its  characterization in 
yeast. In this pathway is the lysosomal membrane itself, which invaginates to form 
tubules or vesicles that sequester cytoplasmic components and organelles [Cuevo et al., 
2010]. 
 
Chaperone-mediated autophagy (CMA) 
CMA is a highly selective autophagy; only proteins with a specific signal sequences are 
recognized from chaperone complexes in the cytoplasm and transported to the 
lysosomes for degradation. Delivery of cargo via CMA does not require formation of 
intermediate vesicle compartments, membrane fusion or membrane deformity; specific 
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receptors (named Lamp2A) localized on lysosomal membrane link chaperone-protein 
complexes and allow their internalization [Cuevo et al., 2010]. CMA allows degradation 
of soluble proteins and requires the presence of three different proteins:   
1. Cytoplasmic chaperones like Hsc70 recognizing signal sequences (KFERQ or 
QREFK), that link and drive proteins to lysosome.  
2. Lamp2A receptors on the lysosomal membrane for the internalization of the 
complex in the lysosomal lumen. 
3. Lysosomal chaperones like Hsc70-Lys indispensable for the transfer in lysosomial 
lumen [Li et al., 2011] 
This pathway is constitutively active in almost all cells, but it is overexpressed during 
stress, like starvation, or in presence of damaged proteins [Orenstein et al., 2010]. It is 
involved in cellular homeostasis maintenance in normal conditions or during stress, 
recently it has been demonstrated its involvement in specialized functions like antigen 
presentation [Zhu et al., 2009].  
 
Macroautophagy 
Macroautophagy is the most important autophagic pathway. It allows the degradation 
of proteins, organelles and  entire cytoplasmic regions. Cargo sequestration occurs in 
the autophagosome, a double membrane vesicle that origins from a series of 
interactions between more than 10 different proteins. The enzymes needed for 
degradation of the sequestered cargo are provided through fusion with lysosomes 
[Cuevo et al., 2009]. This pathway can be divided into different phases (figure 6): 
1. Initiation: the pathway initiation is driven by a complex containing ULK1-2 
(homologous to yeast Atg1), ATG13 and  FIP200 kinases, during cellular stress like 
starvation or low ATP levels. The activated ULK1-2 kinases phosporilate ATG13 
and FIP200 determining the activation of the entire complex and the localization 
near the membrane of the rising phagophore [Jung et al., 2009]; 
2. Autophagosome formation: this phase can be divided in three stage, nucleation, 
elongation and autophagosome completation. For the nucleation is essential a 
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complex composed of phosphatidilinositol-3-kinase, Vsp34, Beclin1 and p150 
that produce PI3P, key component of the autophasomal membrane and of 
protein recruitment [Simonsen et al., 2009]. It’s still unclear the mechanism of 
membrane formation; recently structures, named omegasomes, have been 
discovered; they origin near the endoplasmic reticulum (ER) during aminoacids 
deficiency [Axe et al., 2008]. These structures are rich of PI3P and other proteins 
typically expressed during autophagy, like LC3 and Atg5. The ER could act as a 
platform for PI3P synthesis and protein recruitment [Simonsen et al., 2009]. 
Beclin1 is another important protein in this pathway; it is formed by three 
domains: a N-terminal domain BH3, a central domain with coiled coil structure 
CCD and a C-terminal domain ECD. Everyone of this domain can interact with 
different proteins [Kang et al., 2011]. In condition of abundance of nutrients, Bcl2 
(anti-apoptotic protein) link the BH3 domain of Beclin1 determining the 
detachment from the Vsp34 complex and inhibiting autophagy. The CCD domain 
interacts with Atg proteins like Atg14L, fundamental for  complex assembly, PI3P 
production [Sun et al., 2008] and recruitment of protein like LC3 [Matsunaga et 
al., 2009]. The elongation stage requires two proteins ubiquitin-like, Atg12 and 
LC3. Atg12 is linked to Atg5 trough two enzymes, Atg7 and Atg10. A third protein, 
Atg16L, joins the Atg5-12 complex to form a tetrameric complex. The union of 
more tetramers produce a multimeric complex named ATG16L that acts like a 
platform for the autophagosome elongation [Nakatogawa et al., 2007]. ATG16L 
complex is needed for recruitment on the autophagosomal membrane of LC3 
that has a key role in the elongation stage [Fujita et al., 2008]. The LC3 protein 
exists in two different form, a cytosolic LC3-I and a membrane form LC3-II. The 
cytosolic LC3 is cleaved by a Cys-protease (Atg4) to form LC3-I that is conjugated 
with phosfatidiletanolammine (one of the most important component of cellular 
membranes), generating LC3-II, that remain linked to the autophagosome 
membrane during all the autophagic process [Ohsumi et al., 2001].  
3. Maturation and fusion with lysosome: autophagosome maturation requires 
various fusion events with endosomes, multivescicolar bodies and lysosomes; 
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different proteins are involved in this process, like SNAREs, Rab, ESCRT e Lamp, 
that take part in many pathways of vesicles fusion. Lysosomes usually are located 
in perinuclear position near the Microtubules organization center (MTOC), 
autophagosomes instead can be formed in every region of cytoplasm [Jahreiss et 
al., 2008]. A transport dinein-dependent is fundamental for the transfer of 
autophagosomes to perinuclear region [Ravikumar et al., 2005]. The interaction 
between autophagosomes and dinein is probably mediated by LC3, an injection 
of antibodies anti-LC3 inhibits their movements [Kimura et al., 2008]. The FYCO1 
protein was recently discovered to interact with LC3 and Rab7 to form a complex 
that promote transport along microtubules [Pankiv et al., 2010]. Lysosomial 
proteins Lamp1-2 finally interact with Rab7 to promote autophagosome 
maturation and acidification [Saftig et al., 2008]  
4. Cargo degradation and nutrient release: after autophagosome - lysosome fusion, 
lumen acidification and lipases (like Atg5) activation induce the autophagosome 
membrane degradation [Nakamura et al., 1997]; the proteic components of 
autophagosome are degraded by hydrolases like Pep4. Cargo degradation 
through proteinase A is linked to vesicle acidification determined by H+ATPase 
activation  that induce a pH reduction. Degradation products, like aminoacids and 
monosaccarides are transported in cytoplasm by lysosomal efflux transporters 
(like Aut4, SLC36A1 and LYAAT 1-2) [Lloyd  et al., 1996;  Sagné  et al., 2001; Yang  
et al., 2006]. 
In addition to the degradation and the nutrients recycle, macroautophagy is important 
for cell viability maintenance and it has a key role in various human diseases like cancer 
and neurodegenerative disorders. This pathway is activated as response to different 
stimuli like starvation, ipoxia, oxidative stress, reticulum endoplasmic stress and after  
chemotherapic treatments. Alterations in this pathway can be linked to the 
development of various human pathologies, like tumors, inflammatory diseases and 
neurodegenerative disease. 
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Figure 6: Stages of autophagosome formation and cargo degradation. 
 
Autophagy and cellular homeostasis maintenance 
Autophagy is a very controversial topic. It seems to be important in cellular defence but 
at the same time under stress condition it can induce programmed cell death [de Bruin 
et al., 2008; Chen et al., 2008]. 
This pathway is activated as response to different cellular stress (Figure 7); senescent 
mitochondria, for example, have a more permeable membrane that increases protein 
release (like c citocrome) that induces a pro-apoptotic signal. In this contest mitophagy 
(mitochondria degradation through autophagy) seems to be a cytoprotective pathway 
[Nishida et al., 2009]. Reticulum endoplasmic stress (ER) also can induce autophagy 
activation. ER provides a calcium store and is the site where post-translational 
modification take place. ER homeostasis alteration cause an accumulation of unfolded 
or misfolded proteins that induces the “unfolded protein response” (UPR) [Kaufman et 
al., 2002; Ron et al., 2002]. UPR induces the damaged protein sequestration and the 
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inhibition of mRNA translation to decrease the ER charge. Autophagy activation can help 
ubiquitin-proteasome system in this purpose [Ding et al., 2007; Rouschop et al., 2010].    
 
 
Figure 7: Autophagy protective role in cellular homeostasis maintenance [Nishida et al., 
2009] . 
 
Hypoxia induce autophagy via HIF1α; this protein acts as a sensor detecting oxygen 
concentration lower than 3% [Majmundar et al., 2010] and activates BH3-Only, BNIP3 
and BNIP3L transcription. These proteins link Bcl2 determining its detachment from 
Beclin1 that can induce autophagy [Kroemer et al., 2010]. 
Oxidative stress also could acts as autophagy inducer [Chen et al., 2008]. High levels of 
cytoplasmic ROS induce activation of ATM (Ataxia-Telangectasia Mutated) that 
determine TSC2 phosphorylation by AMPK; active TSC2 inhibits mTORC1 with 
consequent autophagy activation [Alexander et al., 2010]. Alternatively ROS could 
induce MAPKs, like JNK1, that active autophagy [Wong et al., 2010] (Figure 8). Although 
it is still unclear what could be autophagy role, it is known that this pathway is induced 
also by DNA damage [Rodriguez-Rocha et al., 2011]. Cells constantly undergo conditions 
that damage DNA determining block of replication, mutations and sometimes cell death. 
Harmful agents can come from external environment (like ionizing radiations, UV rays, 
alkalizing agents, intercalating agents) or from normal physiological pathways that 
generate ROS or reactive species.
and ATM, are also important autophagy regulators. In presence of DNA damage FOXO3a 
activate transcription of pro-autophagic genes like LC3 and BNIP3 and induce ATM self
phosphorilation and activation [
induce autophagy activation through TSC2 phosphorilation
(Figura 8). 
Figure 8: ATM as autophagy regulator during oxidative or genotoxic stress [Alexander, et 
al. 2010]. 
 
Alternatively DNA damage induce PARP1 (poly ADP
that uses NAD+ and ATP to form poly
polymerase with a consequent imbalance of ADP/ATP ratio
that induces autophagy [Muñoz
 Some important DNA damage sensors, like FOXO3a 
Chiacchiera et al., 2010]. As already seen ATM itself can 
 during oxidative stress
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p53 also can act as autophagy regulator. Under normal conditions cytoplasmatic form of 
p53 inhibits autophagy, but during a genotoxic stress it induces this pathway activating 
the transcription of pro-autophagic genes like PTEN, TSC2 e AMPK and inhibiting mTOR 
[Tasdemir et al., 2008].  
Many studies have shown that alterations in autophagy induce an increase of DNA 
damage and promote tumor and neurodegenerative diseases occurrence, highlighting 
the autophagy role in maintenance of genomic stability [Rodriguez-Rocha et al., 2011]. 
Under DNA damage conditions autophagy could serve as a source of energy during cell 
cycle arrest and for repair mechanisms. On the other hand autophagy seems to act also 
degrading some components of repair machinery [Robert et al., 2011].  
Although autophagy seems to act as surviving mechanism, it is emerging that 
sometimes the final result of autophagic pathway could be cell death, named  type II cell 
death [Levine et al., 2005]. Apoptosis cell death is characterized by membrane 
vesiculation, chromatin condensation and nucleus and cytoplasm fragmentation in 
apoptotic bodies; autophagic cell death instead is characterized by cell shrinkage and 
formation of multiple autophagosomes [Tsujimoto et al., 2005]. While many studies 
have made a distinction between apoptosis and autophagy [Guillon-Munos et al., 2005; 
Reef et al., 2006], others pointed out that the two mechanisms can be interconnected 
[González-Polo et al., 2005; Sadasivan et al., 2006]. Many signaling pathways that 
regulate apoptosis also regulate autophagy (Figure 9) [Zhou et al., 2011]. Beclin1 for 
example induces autophagy and at the same time inhibits apoptosis blocking tBid 
migration to the mitochondria membrane and consequently limiting membrane 
permeabilization. On the other hand active caspases  cut Beclin1 inhibiting autophagy 
[Kang et al., 2011]. Atg5 also regulates both the pathways; It is important for autophagy 
initiation, but its proteolitic cleavage  inhibits autophagy and induces formation of a 
24KDa fragment that migrates to mitochondria promoting membrane permeabilization 
and c cytochrome release [Yousefi et al., 2006]. 
 
Figure 9: interaction pathways between apoptosis and autophagy [Kang, et al. 2011]
 
Autophagy could represent a first cellular attempt during the early damage stages for 
cellular homeostasis maintenance; in presence of
prevails inhibiting autophagy. Autophagy itself can sometimes induce cell death as a 
result of an excessive degradation of cellular components.
accumulation of damaged or misfolded proteins and 
induce cellular or tissue damages. Alterations in this pathway are associated with a 
variety of degenerative processes characterized by movement disorders [
al., 2005; Massey et al., 2006], like in Parkinson dise
et al., 2006; Xilouri et al., 2011
generation of neuronal aggregates and cell death [
 
Alterations in autophagic pathway
Many studies have underlined the relationship between autophagy alterations and 
human diseases development. Tissue specific gene knock
mice have permitted to analyze autophagy role in organs and tissues. 
 an extensive damage apoptosis 
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The inhibition of autophagy in liver determine the accumulation of damaged 
mitochondria in hepatocytes and the emergence of typical symptoms of hepatic 
diseases [Komatsu et al., 2005]. Pathway inhibition in β cells determines an increase of 
cell death during high - calories diet [Jung et al., 2008].  
Basal levels of autophagy seem to be important also during hematopoiesis and for 
muscular and nervous tissue homeostasis. It was demonstrated in 2007 the correlation 
between autophagy deficiency and Crohn’s disease [Rioux et al., 2007]. Among diseases 
associated with autophagy alterations there are neurodegenerative diseases like 
Parkinson’s disease, Huntington Corea and Alzheimer’s disease, cancer and cardiac 
diseases.   
 
Neurodegeneration 
Proteic aggregates formation in the cytoplasm of neuronal cells is a common feature of 
many neurodegenerative diseases. Some examples are the Lewy’s bodies, constituted of 
α- Sinuclein accumulation in Parkinson’s disease, or the huntingtin’s aggregates in 
Huntington’s disease. The toxicity of these aggregates is due to their capacity to 
aggregates each other and with other proteins. Usually these aggregates can be 
sequestered by autophagosomes and eliminated [Mariño et al., 2011].   
Alzheimer’s disease (AD) also is characterized by the formation of cytoplasmic Tau 
proteins aggregates and the accumulation of extracellular aggregates, named amyloid 
plaques, constituted of β- amyloid protein. In AD patients’ brain is visible an 
accumulation of autophagosomes and autolysosomes. An overexpression of autophagy 
in neuronal cells seems to reduce intracellular levels of β-amyloid and Tau proteins, and 
at the same time a reduction of amyloid plaques deposition, determining a 
neurodegeneration reduction [Mariño et al., 2011]. As in all finally differentiated cells, 
autophagy has a primary role in neurons. In this cells cellular waste can’t be redistribute 
in daughter cells and a reduction of autophagy levels induce a organelles/proteins 
accumulation that contribute to accelerate neurodegenerative process. The 
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pharmacological regulation of autophagy with inhibitors or inducers could represent a 
new therapeutic approach of various neurodegenerative diseases. 
  
Autophagy and cardiac tissue homeostasis 
Cardiac tissue is continuously subjected to stress; a rapid turn-over of cellular 
components is indispensable in physiological conditions also. As for neurons autophagy 
is a key pathway to maintain cellular homeostasis in cardiomyocytes reducing cellular 
waste. Moreover cardiomyocytes are long life cells and for this motif susceptible to 
aging that can hit cellular structures like mitochondria and lysosomes.  Numerous 
studies have demonstrated that alterations in autophagic pathway induce cardiac 
dysfunctions; Atg5 deficient mice died after birth and showed a low free aminoacid 
concentration  and a lack of energy in cardiac cells [Kuma et al., 2004]. Atg5 knockout in 
mouse’s hearth induced a cardiac hypertrophy, ventricular dilatation and contractile 
dysfunctions, associated with proteic aggregates and damaged mitochondria 
accumulation in cytoplasm [Nakai et al., 2007]. Removal of mitochondria is particularly 
important during ischemia/reperfusion injury because oxygen starvation and 
subsequent re- oxygenation leads to the uncoupling of oxidative phosphorylation, 
opening the mitochondrial permeability transition pore, and subsequent pro-apoptotic 
factors release and damages to the mitochondria induction [Halestrap et al., 2007]. It 
has been demonstrated that ischemia induces autophagy up-regulation through various 
factors. Hypoxia in cardiomyocytes for example activates BNIP3 that induce autophagy 
inhibiting Bcl2; during energy lack autophagy is induced by AMPK an indicator of 
ADP/ATP ratio. If during ischemia autophagy represents an adaptive response to stress 
condition, its upregulation during reperfusion can induce autophagic cell death (Figure 
10) [Ravikumar et al., 2010]. 
It remains still unclear the real role of autophagy in the heart, its protective or adverse 
effects on cells seem depend on the different pathways that participate in (figure 10). 
Better understanding the autophagic pathway could allow the development of new 
drugs that can improve the cellular energetic metabolism in cardiac cells under stress 
conditions [Loos et al., 2011]. 
Figure 10: Different autophagy roles during ischemia and reperfusion [Ravikumar, et al. 
2010]. 
 
Cancer and autophagy: suppressor or promoter of 
The autophagy role in cancer is complex and highly discussed. 
autophagy is a protective system able to prevent accumulation 
damaged organelles that could promote 
acting as cancer suppressor. On the other hand the capability to allow surviving in 
cancer cell under stress conditions, like hypoxia and starvation, gives to autophagy an 
important role in tumor growth and progression. In this contest the autophag
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microenvironment. Between the autophagic genes with suppressor features there are 
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higher probability to develop cancer than w
Moreover mutations in pro-
detected in various cancers. A monoallelic mutation of Beclin1 has been found in 40
70% of breast, ovarian and prostatic sporadic tumor
elimination of mitochondria, named mitophagy, seems to have a key role in tumor 
 
tumor growth?
It is known that 
of cellular waste and 
the conversion of healthy cells 
d of tumor, cancer genetic features and 
-2. Atg4 knockout mice treated with carcinoge
ild type mice [Mariño et al., 2007
autophagic genes, like UVRAG and Beclin
s [Liang et al., 1999
29 
 
 
in cancer cells, 
y role can 
ns had an 
]. 
1, have been 
-
]. The 
30 
 
suppression; this pathway allows to control ROS production, preventing DNA damage 
and metabolic alterations under stress conditions [Karantza-Wadsworth et al., 2007; 
Mathew et al., 2007]. In presence of autophagic defects cancer seems characterized by 
p62 accumulation that induces ROS production and an increase of DNA damage 
[Mathew et al., 2009]. On the other hand high levels of autophagy have been registered 
in tumor regions more subjected to metabolic stress, acting as tumor promoter [Roy et 
al., 2010]. Furthermore the  PI3K/Akt/mTOR pathway, one of the higher autophagy 
regulators, is often altered in many tumors; conversely no homozygosis mutations in 
Beclin1 have been found in cancer cells. Beclin1 deletion in cancer cells decrease tumor 
growth and increase apoptotic cell death [Karantza-Wadsworth et al., 2007]. 
Pharmacological autophagy inhibition in colorectal cancer induces cell death from 
nutrient lack, hypothesizing that this pathway provide energy for cellular growth, 
proliferation and survival [Sato et al., 2007]. Degenhardt demonstrated that autophagy 
is highly induced in regions exposed to hypoxic stress, promoting surviving. This finding 
is really important because hypoxic condition due to low vascularization is associated 
with severe phenotype, with high predisposition to metastasis. Under hypoxic condition 
HIF1α induces transcription of genes involved in angiogenesis and autophagy. In this 
contest autophagy appears to promote tumor proliferation [Degenhardt et al., 2006]. 
In order to better understand the dual role of autophagy we can take as an example the 
stromal tumor. Cancer cells induce oxidative stress in adjacent stromal fibroblasts that 
activate autophagy determining high degradation of mitochondria. Mitochondrial pool 
reduction drives fibroblasts to use aerobic glycolysis with consequent lactate and 
glycolytic intermediate release in extracellular microenvironment. These components 
can serve as fuel for the adjacent tumor cells. Moreover the increase of ROS in 
extracellular environmental due to oxidative stress in fibroblasts induces casual 
mutations in adjacent epithelial cells promoting genomic instability and tumor 
evolution. Tumor growth seems to be promoted by autophagy and stromal fibrobalsts 
that provide energy. On the other hand direct induction of autophagy in epithelial 
tumor cells trough HIF1α induces a drastic reduction of tumor growth. Autophagy 
31 
 
activation can promote or suppress tumor progression depending on the cell type in 
which it occurs [Martinez-Outschoorn et al., 2010]. 
 
Anticancer drugs and autophagy 
Autophagy induced through chemotherapy treatments can have a positive or negative 
effect on cell viability, according to the kind of tumor treated and the drug utilized. 
Sometimes autophagy can induce treatment resistance as, for example, in esophageal 
cancer cells treated with 5-fluoracil [O’Donovan et al., 2011], or in gastrointestinal 
stromal tumor cells (GIST) treated with Imatinib mesylate [Gupta et al., 2010] and in 
pulmonary cancer cells treated with Cetuximab [Li et al., 2010]. In other cases 
autophagy can help drug action inducing cancer cells death as for example Ewing’s 
sarcoma cells treated with 2-Metoxyestradyol [Lorin et al 2009], or in glioma cells 
treated with Temozolomide (Figure 11) [Voss et al., 2010].  
 Autophagy activation has been observed after treatment both with traditional 
chemotherapy like Doxorubicin or Daunorubicin than with new generation drugs like 
targeted therapies [Wu et al., 2011] 
Figure 11: Autophagy activation after chemotherapy treatment [Wu, et al. 2011].
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This thesis is the result of a research program made in collaboration between the Life 
Sciences Department and the Clinical and Experimental Medicine Department of the 
University of Parma in a project supervised by Professor F. Quaini in collaboration with 
Professor A. Buschini. Principal aim of this study was to evaluate Imatinib mesylate (IM) 
controversial effects on cellular and on organ- systemic level. To reach this goal I 
peformed in vitro assays like: cytotoxicity assay MTS, single cell gel electrophoresis 
(SCGE or Comet assay) to determine genotoxicity, the assessment of autophagy through 
a fluorescent assay and the evaluation of gene expression modification through real 
time PCR (RT-PCR). The adverse effects of IM could be due to inhibition of aspecific 
tyrosine kinases. It is known that IM can link, even if with minor affinity, other proteins 
like c-kit that is fundamental for cardiac stem cells (CSC) and cardiac resident stem cells 
(CRSC) differentiation in cardiomyocytes and for CSC migration from bone marrow to 
hearth. Alterations in stem cell migration and maturation could prejudice their 
capability to replace damaged tissue and repair lesions, increasing the possibility of 
cardiac diseases development. To investigate the possibility that this drug could 
compromise integrity of stem cells, the activity of IM has been evaluated on two cardiac 
stem cells lines (rat cardiac progenitor cells- CPCs and human cardiac mesenchimal stem 
cells- C-MSCs). Furthermore I have compared IM effects on these stem cell lines with 
that induced on IM target cell line K562 (chronic myelogenous leukemia cell line). 
Since oxidative stress seems to be involved in IM toxicity I’ve assessed through a 
fluorescent assay the formation of reactive oxygen species, and their effects on cell 
physiology evaluating autophagic pathway  activation (through a transfection assay) and 
the variations in gene expression after IM treatment by RT-PCR. 
To evaluate the role of autophagy induced by IM treatment I have analyzed the effects 
of co- treatments with autophagic regulators. Autophagy is a complex pathway that 
could be regulated by different stimuli. Numerous are the molecules that can interact 
with proteins involved in this process, inducing its activation or inhibition. Among 
autophagy inducers rapamycin and lithium salts (LiCl e LiHCO3) are the most used for in 
vitro studies. Rapamycin is a natural antibiotic isolated from Streptomyces 
hygroscopicus that inhibits mTOR kinase activity, allowing the formation of 
ULK1/FIP200/Atg13 autophagy start complex [Ravikumar B, et al. 2010]. Lithium salts 
are used for treatment of neurological disorders. Lithium action is mTOR
and interferes in phosphoinositol pathway; it
involved in IP2 conversion into free inositol that induces a decrease of intracellular levels 
of IP3 and  the inhibition of IP
Moreover lithium induces decrease
[Sarkar S, et al. 2006]  (Fig. 12).  
Figure 12: Mechanism of action of autophagy inducers that are involved in 
phospoinositol pathway [Sarkar S, et al. 2006]
 
Autophagy inhibitors can also act in different
autophagy in initial phase or during the degradation of autophagosomal content (Fig. 
13). Among the molecules that act upstream in the autophagic pathway there are 3
Metiladenine (3-MA) and Wortmannin. They link Vps
interfere with the autophagosomal nucleation [Kroemer G, et al. 2005]. Between the 
downstream inhibitors we can find cloroquine (CQ) and hydroxychloroquine (HCQ), two 
 inhibits two enzymes, IPPase and IMPase, 
3 receptor (IP3R), driving to autophagy activation. 
 of inositol blocking inositol transporter (SMIT) 
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Figure 13: Inhibitors of different steps of the autophagic pathway.
 
Since autophagy can represent a defence mechanism during chemotherapic treatment, 
their role of autophagic inhibitors made CQ and HCQ ideal candidates for the 
development of new antitumor therapies. Numerous phase I and II studies are 
evaluating the combined administration of CQ or HCQ and chemotherapic drugs [
Z,et al. 2011] (tab. 1).  
CQ/HCQ and lithium chloride are drugs used for many years in treatment of human
diseases, so their absorption kinetics and collateral effects are known. This aspect led 
me to use during my study  lithium chloride as autophagic 
inhibitor.  
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Table 1: Clinical and pre-clinical phase studies that use CQ and HCQ as autophagy 
inhibitors during tumor treatment [Yang Z,et al. 2011]. 
 
In the last period of my work I have compared the in vitro effects induced on target and 
non- target cell lines by IM treatment with those induced by a drug with known 
cardiotoxic effects. For this reason I have used doxorubicin, an old generation 
chemotherapy. Doxorubicin effects have been evaluated on a human breast 
adenocarcinoma cell line (MCF7), target cell line of doxorubicin, and on human cardiac 
mesenchimal stem cells (C-MSCs).  
Tumor type Development status Therapeutic combination 
Colorectal cancer 
In vitro, in vivo 
 
Phase II 
CQ + bortezomib 
CQ + vorinostat  
HCQ + XELOX + bevacizumab 
Gastrointestinal stromal tumor In vitro, in vivo CQ + Imatinib 
Prostate cancer In vitro, in vivo CQ + Src Kinase inhibitors 
Vulvar cancer In vitro CQ + cetuximab 
Chronic myelogenous 
leukemia 
In vitro 
PhaseII 
CQ + vorinostat  
HCQ + Imatinib 
Lymphoma in vivo CQ + cyclophosphamide 
Pancreatic cancer 
Phase II 
Phase I/II 
HCQ only 
HCQ + gemcitabine 
Prostate cancer Phase II HCQ + docetaxel 
Lung cancer Phase II HCQ + erlotinib 
Glioblastoma multiforme Phase I/II 
HCQ + temozolomide + 
radiation 
Multiple myelome Phase I/II HCQ + bortezomib 
Renal cell carcinoma Phase I HCQ only 
Breast cancer Phase II HCQ only 
Chronic lymphocytic leukemia Phase II HCQ only 
Advanced solid tumor 
Phase I 
Phase I 
Phase I 
Phase I 
HCQ + sirolimus or vorinostat 
HCQ + temsirolimus 
HCQ + sunitinib 
HCQ + temozolomide 
Abbreviations: CQ, chloroquine; HCQ hydroxychloroquine 
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Cell culture 
In vitro effects of IM were investigated on a human chronic myeloid leukemia cell line, 
K562, on a rat cardiac progenitor cell line (CPCs), isolated from untreated rat hearth as 
described by Beltrami and collaborators trough Langhendorff  perfusion apparatus [Leri 
et al, 1999], and on a human cardiac mesenchimal stem cell line (C-MSCs), obtained 
from human bone marrow.  Doxorubicin activity was evaluated using a human breast 
adenocarcinoma cell line (MCF7) as target cell line and  the human cardiac mesenchimal 
stem cell line, C-MSCs. Prior to the experiments, cells were thawed and grown in tissue 
culture flasks as monolayer in IMDM (Iscove’s Modified Dulbecco’s Medium), 
supplemented with 1% L- glutamine (2mM), 1% penicillin (5000U/ml)/streptomycin 
(5000 µg/ml), 1% ITS (insulin, transferrine sodium selenite) and 10% fetal bovine serum 
(FBS), or RPMI (Roswell Park Memorial Institute) or DMEM (Dulbecco’s Modified Eagle 
Medium), supplemented with 1% L- glutamine (2mM), 1% penicillin 
(5000U/ml)/streptomycin (5000 µg/ml) and 10% fetal bovine serum (FBS) at 37°C in a 
humidified CO2 (5%) incubator. The cardiac cell lines were trypsinized with trypsin/EDTA 
for a maximum of 5 min and seeded with a subcoltivation ratio of 1:3-1:8. 
Determination of cell numbers and viabilities was performed with the trypan blue 
exclusion test. 
 
Antiproliferative activity 
The antiproliferative activity was evaluated by a colorimetric assay that allows us to 
determine the number of viable cells in proliferation. This assay (CellTiter96R AQueous 
One Solution Cell Proliferation Assay, Promega Corporation, Madison, WI, USA)  
contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an 
electron coupling reagent (phenazine ethosulfate; PES). The MTS tetrazolium compound 
is bioreduced by cells into a colored formazan product that is soluble in tissue culture 
medium. This conversion is accomplished by NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells. In order to determine cell viability, 
in the exponential phase of growth, cells were seeded at 5 x 104/ml in 96-well plates, in 
IMDM or RPMI or DMEM. After seeding (24h), cells were treated, in quadruplicate, with 
5-50 μM IM or 5 μM IM/3 μM chloroquine or 5 μM IM/10mM Lithium chloride and 
incubated for 6-12-24-48h. The cytotoxicity assay was performed by adding a small 
amount of the CellTiter96R AQueous One Solution Cell Proliferation Assay directly to 
culture wells, incubating for 4h and then recording the absorbance at 450 nm with a 96-
well plate reader (MULTISKAN EX, Thermo Electron Corporation, Vantaa, Finland).  
The same experimental protocol was 
after treatment with 0.1 ÷50 μM Doxorubicin.
 
 
Comet assay   
The Comet Assay or Single-Cell Gel Electrophoresis (SCGE) assay is a
for assessing DNA damage evaluating the presence, after electrophoresis, of  
fragmented DNA outside the core of the nucleus
fragments, negatively charged
the appearance of a comet (fig. 14)
the comet indicates the extent of the DNA damage. This quantity is dependent on the 
size of DNA fragments and the number of broken ends in the strands. 
 
 
Figure 14: An example of DNA molecule visualized through Comet Assay.
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oxidation of the nitrogenous base
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Agarose 0.7% (LMA), transferred onto degreased microscope slides previously dipped in 
1% Normal Melting Agarose (NMA) for the first layer. The agarose was allowed to set for 
15 min at 4°C before the addition of a final layer of LMA. Cell lysis was carried out at 4°C 
overnight by exposing the cells to a buffer containing 2.5 M NaCl, 100 mM Na2EDTA, 8 
mM Tris-HCl, 1% Triton X-100 and 10% DMSO, pH 10. The electrophoretic migration was 
performed in an alkaline buffer (1 mM Na2EDTA, 300 mM NaOH, 0°C) at pH>13  (DNA 
unwinding: 20 min; electrophoresis: 20 min, 0.78Vcm-1, 300mA). DNA was stained with 
75 µl ethidium bromide (10 µg/ml) before the examination at 400x magnification under 
a Leica DMLS fluorescence microscope (excitation filter BP 515-560 nm, barrier filter LP 
580 nm), using an automatic image analysis system (Comet Assay III – Perceptive 
Instruments Ltd, UK). Total % fluorescence in tail (TI, tail intensity) provided 
representative data on genotoxic effects. For each sample, coded and evaluated blind, 
100 cells were analyzed and the mean value of TI was calculated.  
The same experimental protocol was applied on MCF7 cell line and C-MSCs cell line  
after treatment with 1-10-100 μM Doxorubicin. 
 
Measurement of reactive oxygen species (ROS) production 
ROS production was measured by fluorescence assay, using 2',7'-dichlorfluorescein-
diacetate (DCFH-DA - Sigma). DCFH-DA is a nonfluorescent compound that can pass 
through cell membranes. Once it is in the cytoplasm, cellular esterases remove the 
acetates to produce 2', 7'-dichlorodihydrofluorescein (DCFH), which because of its 
polarity is not cell permeable. DCFH is easily oxidized to 2', 7'-dichlorofluorescein (DCF), 
an highly fluorescent compound [E. J. Bland et al., 2001]. In a typical experiment cells 
seeded at 2,5 x 105/ml in 6-well plates in IMDM or DMEM or RPMI supplemented as 
described above. After seeding (24h), cells were washed with PBS and pre-incubated for 
30 min (37 °C) with DCFH-DA (10 μM) which was added from a stock solution in DMSO 
and diluted in PBS. The quantity of DMSO never exceeded 0.1%, and was also added to 
the blank. Cells were washed with PBS to remove extracellular DCFH-DA and treated 
with 1-5 μM IM and incubated at 37°C for 3h. Then medium was removed, and a 
solution of Tris–HCl-TritonX and a cell dissociation solution (Sigma) was added for 10 
min. Cell lysates were scraped from the dishes and the extracts were centrifuged. The 
supernatant was collected, and the fluorescence was immediately read with a 
fluorescence spectrophotometer (Cary Eclipse, Varian, Palo Alto, CA, USA) looking at the 
fluorescence peak between 510 and 550 nm (excitation = 480 nm).  
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Autophagy assessment 
Autophagic pathway activation has been evaluated through a transfection protocol 
using a plasmid encoding the autophagosome marker LC3 fused with the fluorescent 
protein EGFP (pEGFP-LC3 human, Addgene). Transfection is performed using 
LipofectamineTM reagent (Invitrogen®), consisting of lipidic subunits that can form 
liposomes in an aqueous environment that entraps plasmid and drives it inside cells. 
Transfection allows cells a constitutive LC3-EGFP fusion protein synthesis. Its nuclear 
and cytoplasmic  distribution confers an uniform fluorescence to the cell; autophagy 
activation induces the formation of LC3-EGFP aggregates that determine the fluorescent 
signal amplification, conferring a punctuated morphology with green spot in cytoplasm 
exclusively (fig. 15). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: left panel: example of transfected cells; right panel: example of transfected 
and autophagic cells. 
 
 For the assay execution 2.5*103 cells were seeded in 1ml of growth medium in cell 
chamber slides and incubated at 37°C. After  24h cells were trasfected with the plasmid 
described above according to the following protocol: 4 μg of plasmid were diluted in 
200 μl of Opti-MEM (Invitrogen®), at the same time as 5 μl of Lipofectamine™ are gently 
mixed with 200 μl Opti-MEM. After a first incubation of 5–10 min, the diluted plasmid 
solution and diluted Lipofectamine™ solution were gently mixed and incubated for 
another 20 min to promote the formation of Lipofectamine™:plasmid complexes; 30 μl 
of solution containing the Lipofectamine™:plasmid complexes were added to each well 
and cells incubated at 37°C in 5% CO2 atmosphere for 24 h. At the end of transfection 
cells were treated with 5-50 μM IM or with 0.5-1 μM Doxorubicin for 6-12-24 h. After 
treatment growth medium was removed, cells were washed twice with PBS and fixed in 
400 μl of fixative solution for 30 min at RT; fixative solution was removed, cells were 
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washed three times with PBS, chamber slides were disassembled and cover slips were 
mounted onto slides using Vectashield mounting medium with DAPI. For the 
visualization of LC3-EGFP aggregates, cells were examined through a fluorescent 
microscopy using an oil immersion objective (100× magnification). For each sample 200 
transfected cells were analyzed; in autophagy negative cells LC3-EGFP exhibits a diffuse 
cytoplasmic signal; when autophagy is induced, LC3-EGFP chimeric proteins aggregate in 
autophagic vacuoles, leading to a punctuate cytoplasmic staining [E. Tasdemir et al., 
2008]. 
 
Quantitative real time- PCR (RT- PCR) 
A quantitative real-time PCR was performed to evaluate the expression of genes 
involved in DNA damage checkpoints (ATM and ATR) and in autophagy (LC3, Beclin1, 
mTOR, Bcl2).  The use of an housekeeping gene as Actina B (ActB) allows relative 
quantification of gene expression. This method consists of three phases: RNA extraction, 
c-DNA synthesis and RT-PCR. 
 
RNA extraction:  
Total RNA extraction was performed through  RNeasy Mini Kit (QIAGEN); 1-2*106 cells 
were seeded in Petri plates in 12 ml of growth medium and incubated 24h at 37°C ; then 
cells were treated with 1-5 μM IM for 3-12h or with Doxorubicin 0.5-1 μM. After 
treatment a single cell suspension was obtained; cells were disrupted in Buffer RLT and 
homogenized by a 20 gauge syringe needle. Then Ethanol was added to the lysate, 
creating conditions that promote selective binding of RNA to the RNeasy membrane. 
The sample was then applied to the RNeasy Mini spin column. Total RNA binds to the 
membrane, contaminants were washed away by washes and centrifugation in a 
microcentrifuge. Then RNA was eluted in nuclease-free water. Eluted RNA concentration 
was evaluated through spectrophotometer Eppendorf Biophotometer. 
 
c-DNA synthesis: 
2.5 μg RNA were used for c-DNA synthesis. A Genomic Elimination Mixture (GE) was 
prepared in a sterile PCR tube as follows: 
 
Total RNA     2.5-5 μg 
GE (5x gDNA Elimination Buffer)          2.0    μl 
H2O  To  10.0 μl 
Total volume 10.0  μl 
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GE was mixed, centrifuged and incubated at 42°C for 5’ and then transferred in ice for 
1’. A retrotranscriptase cocktail (RT-cocktail) was prepared as follows:   
 
RT Cocktail 1 reaction 
BC3 (5x RT Buffer 3) 4 μl 
P2 (Primer & External Control Mix) 1 μl 
RE3 (RT Enxzyme Mix 3) 2 μl 
H2O 3 μl 
Total volume 10 μl 
 
10 μl of RT-cocktail were added to every 10 μl of GE and incubated at 42°C for 15’; 
reaction was then inactivated at 95°C for 5’. 91 μl of H2O were added to every 20 μl of 
reaction and sample were stored at -20°C till next step. 
 
Real time PCR: 
Every PCR reaction was performed in triplicate preparing a reaction mix as follows: 
 
 RT2 SYBR Green qPCR Master Mix 12.5 μl 
H2O 10.5 μl 
gene-specific 10 μM PCR primer pair stock 1.0  μl 
RT2 First-Strand cDNA (template) 1.0  μl 
Total volume 25.5 μl 
 
PCR reaction was performed through a thermocycler using the following program:  
 
Cycles Time Temperature 
1 10 minutes 95°C 
 
40 
15 seconds 95°C 
30 seconds 55°C 
30 seconds 72°C 
 
 
Statistical analysis 
Data reported in this thesis have been evaluated through SPSS 21.0 (Inc., Chicago, 
Illinois, U.S.A.). A univariate variance analysis (ANOVA) has been performed, followed by 
Bonferroni multiple comparison post-hoc test. 
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Evaluation of in vitro IM effects  
 
As first step of this work I have evaluated the cytotoxicity induced by Imatinib mesylate 
(IM) treatment in K562 cell line and in cardiac cell lines, CPCS and C-MSCs. I have chosen 
to use two doses of IM: 5 μM, comparable with plasmatic drug dose in patients after in 
vivo treatment, and 50 μM to induce an acute response to mimic drug accumulation due 
to a prolonged treatment.  
 
Cytotoxicity 
IM treatment induces cytotoxicity, evaluated through MTS assay, in all the cell lines 
analyzed in a dose and time dependent  manner. In particular an high cytotoxicity is 
detectable in K562 cell line with both tested doses: the higher dose (50µM) induces a 
significative cytotoxicity at all time points analyzed (p<0.001), meanwhile 5 μM IM 
induces a significant reduction of cell number in culture only after 24h treatment 
(p<0.001) (Fig. 16). High cytotoxicity is detectable with IM 50 μM (p<0.001) (fig. 17a-b) 
in the two cardiac cell lines, the lower dose induces a significant reduction of cell 
proliferation only in CPCs cell line after 24h treatment (p<0.01) (fig. 17a). 
 
 
 
Figure 16 -  cytotoxicity (MTS assay) induced on K562 cell line after  24 and 48 h 
treatment with  Imatinib mesylate (5-50 μM) represented   in terms of cell number in 
culture (cell number *102); NT= untreated 
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Figure 17 -  cytotoxicity (MTS assay) induced on CPCs (a) and C-MSCs (b) cell lines after  
24 and 48 h treatment with  Imatinib mesylate (5-50 μM) represented   in terms of cell 
number in culture (cell number *102); NT= untreated 
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The high toxicity found in non
involved in treatment response. I have considered different cellular endpoints related to 
cellular stress: genotoxicity, reactive oxygen species (ROS) production  and induction of 
autophagy. 
 
Genotoxicity  
The induction of DNA damage has been evaluated through the Alkaline version of 
Comet Assay; this version of Comet Assay 
single and double strand breaks, and "alkali
apirimidinic sites, oxidation of the nitrogenous bases, etc.)
on the different cell lines after treatment with 5
of DNA migration, related to DNA damage induction, is detectable after IM trea
the cell lines tested. 
 
K562: IM treatment induces a significant increase of DNA migration in all tested time 
(p<0.001) (fig. 18); the high genotoxicity found after 3h of IM treatment seems to 
reduce over time. This behavior could be explained as 
DNA damage or as a selection of a resistant cell population; this thesis could be 
confirmed by data of cytotoxicity reported above (fig. 
 
 
Figure 18: Genotoxicity (Comet assay) in 
with  Imatinib mesylate (5-50 μM) evaluated in terms of percentage of DNA in comet tail 
(tail intensity : TI%); NT= untreated; T= treated.
0
20
40
60
80
T
I 
(%
)
- target cell lines led me to investigate the mechanism 
is usually performed at pH> 13 to detect 
-labile" sites (adducts, apurinic and 
. Comet Assay was performed 
-50 μM IM for 3-6-12-24h. An increment 
the capability of cell to recover 
16)  
K562 cell line after  3, 6, 12, 24 h treatment 
 
K562
48 
tment in 
 
CPCs: 50 μM IM induces a relevant increase of genotoxicity with time (p<0.
19a); no significant increase in DNA migration is detectable after 5 μM IM treatment
C-MSCs: 50 μM IM determines an high rate of DNA damage (p<0.001) that culminates 
with an acute toxicity after 24 h treatment (fig. 
17b); 5 μM IM induces a significative migration only after 12 hours 
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Reactive Oxigen Species (ROS) detection  
The early induction of DNA damage in cells treated with xenobiotics could be related to 
ROS production. What I detect through Comet Assay, a rapid increment of DNA 
migration especially in K562, drives me to analyze the ability of IM to induce oxidative 
stress. A fluorescent assay, after 1-5 μM IM treatment, was performed on K562 and 
CPCs cell lines; an increase of reactive oxygen species was registered in both cell lines 
(tab. 2). The use of Menadione (25 μM) as a positive control allowed me to compare the 
oxidative stress induced by IM with the one induced by a known oxidant. Interestingly 
CPCs seem to have an higher resistance against oxidative stress as shown by the 
different impact of Menadione on this cell line than on K562 cell line.     
 
 ROS increment (%) 
Cell line IM 5µM Menadione 
K562 300,15 1224,15 
CPCs  20,70     47,04 
 
Table 2:  ROS induction in K562 and CPCs cell lines after 3h IM (5 μM) and Menadione 
(25μM) treatment, expressed in terms of ROS increment percentage. 
  
Autophagy  
Autophagy was evaluated as mechanism of cellular stress response. A transfection assay 
was conducted using a plasmid 
fluorescent protein EGFP (Fig. 20)
 
 
 
 
 
 
 
 
 
 
Figure 20: left panel: example of 
and autophagic cells. 
 
An evident activation of autophagic pathway was found in 
22).  
Because of the high cytotoxicity induced by IM
cell line after 50 μM IM treatment was 
21). Interestingly basal levels of autophagy in cardiac cells seem to be higher than in 
K562 cell line (fig. 22a- b). 
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Figure 22: Autophagy induction in CPCs (a) and C
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Evaluation of transcriptional profile  
To confirm the involvement of DNA damage response and autophagic pathways, a 
quantitative real time PCR (RT-PCR) was performed on K562 and C-MSCs cell lines after 
12h treatment with 1-5 μM IM. The higher dose (50 µM) hasn’t been used because of 
the high cytotoxicity that it induces in all cell types. Furthermore, I introduce a subtoxic 
dose (1 μM IM) to better understand the biological activity of the drug. 
I have analyzed the expression of genes encoding the proteins involved in DNA damage 
response, ATM and ATR, and genes encoding the proteins involved in autophagic 
pathway, LC3 and Beclin1, that have a key role during autophagic pathway,  and mTOR 
and Bcl2, that act as regulators of autophagy. 
The activation of ATM and ATR genes in K562 cell lines confirms the induction of DNA 
damage (fig. 23a) and, at the same time, the induction of LC3, Beclin1, Bcl2 and mTOR 
(fig. 24a) demonstrates the involvement of autophagy. Interestingly the activation of 
transcription seems to be higher after treatment with the lower dose than with the 
higher one. This reduction of gene expression observed with 5µM IM could be due to 
the reduction of cell proliferation observed with MTS assay (fig. 16). 
In C-MSCs cell line a variation of transcriptional levels of gene involved with autophagy 
is observable only with the higher dose (5 μM) (fig. 24b). On the other hand, a 
significant induction of  ATR, a gene encoding the a protein activated in response to 
DNA damage and cell cycle arrest during replication, is observable with both the 
concentrations used. Surprisingly ATM, encoding a protein activated in presence of DNA 
double strand breaks,  doesn’t show variation in expression after IM treatment (fig. 
23b). 
 
Gene 
K562 C-MSCs 
ΔΔCt (1 μM) ΔΔCt (5 μM) ΔΔCt (1 μM) ΔΔCt (5 μM) 
ATM -4,84 -0,44 4,49 1,75 
ATR -3,46 -0,21 -7,10 -11,33 
LC3 -2,88 -0,78 0,61 -3,94 
Beclin1 -2,53 -1,03 0,16 -3,23 
mTOR -1,28 0,07 0,40 -4,33 
Bcl2 -3,72 0,47 3,50 -1,37 
 
Table 3: mRNA expression of genes involved in DNA damage response and in autophagy 
in K562 cell line and in C-MSCs cell line after 1-5 μM IM treatment.  
ΔΔCt values = ΔCt of treated − ΔCt of control;  ΔCt = (Ct of sample − Ct ActB) 
  
Figure 23: evaluation of expression of genes involved in DNA damage cell response after 
IM (1- 5 μM) treatment in K562 cell line (a) and in C
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 Figure 24: evaluation of expression of genes involved in apoptotic and autophagic 
pathways after IM (1- 5 μM) treatment in K562 cell line (a) and in C
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Autophagy modulation 
 
The evidences that autophagy could have a key role in chemotherapy, as pro-survival or 
pro-death mechanism, led me to investigate the role of autophagy in IM treatment. Co- 
treatments with IM 5 μM and autophagy regulators were performed; CQ/HCQ 
(autophagy inhibitor) and lithium chloride (autophagy inducer) are drugs used for many 
years in treatment of human diseases, so their absorption kinetics and collateral effects 
are known. This aspect led me to use these two molecules during my study. 
 
Cytotoxicity   
A variation in terms of cell number in culture was detected in all tested cell lines; in 
particular in K562 cell line autophagy inhibition through cloroquine induces a reduction 
of cell proliferation (p<0.01), conversely autophagy activation by lithium chloride 
improves survival in this cell line (p<0.001) (fig. 25). In the two cardiac cell lines both 
chloroquine and lithium chloride induce a reduction of cell proliferation after 24h 
treatment compared to the cell population treated with only IM (CPCs p<0.01; C-MSCs 
p<0.001)(fig. 26a- b).   
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(MTS assay) induced on 
K562 cell line after 24h 
treatment with  Imatinib 
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Figure 26: cytotoxicity (MTS assay) induced on CPCs (a) and C-MSCs (b) cell line after  24 
h treatment with  Imatinib mesylate (5 μM), Imatinib mesylate plus chloroquine or 
Imatinib mesylate plus lithium chloride represented   in terms of cell number in culture 
(cell number *102); NT= untreated, CQ= chloroquine, LiCl= lithium chloride. 
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Genotoxicity  
To evaluate variation in DNA damage the alkaline version of Comet Assay has been 
performed on human cell line
hours. I used different treatment times in relation with the time course of DNA damage 
induction for each cell line analyzed. A variation of DNA damage represented in terms of 
percentage of tail intensity was detected in all tested cell lines after co
IM and autophagy inhibitor Ch
the two human cell lines: both in K562 tha
reduction of DNA damage (fig. 
line could be related to high rate of cytotoxicity observed through MTS assay (
 
 
Figure 27: Genotoxicity (Comet assay) in K562 cell line after  treatment with  Imatin
mesylate (5 μM) and Imatinib mesylate plus chloroquine evaluated in terms of 
percentage of DNA in comet tail (tail intensity : TI%); 
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 Figure 28: Genotoxicity (Comet assay) in 
mesylate (5 μM) and Imatinib mesylate plus chloroquine evaluated in terms of 
percentage of DNA in comet tail (tail intensity : TI%); 
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Evaluation of in vitro Doxorubicin effects  
 
To compare the in vitro effects observed after IM treatment with those induced by 
molecule with known cardiotoxic activity I used doxorubicin, an old generation 
chemotherapy. The effects induced by Doxorubicin treatment have been evaluated on 
MCF7, doxorubicin target cell line, and on C-MSCs cell line. 
  
MCF7 cell line: 
The cytotoxicity evaluation on MCF7 (Doxorubicin target cell line) treated with 
Doxorubicin (0.1, 0.5, 1, 10 μM) for 24 and 48 hours shows a reduction of cell 
concentration for all testes doses (fig. 29). DNA damage induction was evaluated 
through Comet assay on cells treated with doxorubicin (1-10-100 μM) for 4 and 24 
hours; as expected a time and dose dependent genotoxicity is induced in MCF7 cell line 
(p<0.001) (fig. 30). 
 
 
 
 
Figure 29: Cytotoxicity (MTS assay) induced on MCF-7 cell line after  24 and 48 h 
treatment with doxorubicin (0.1, 0.5, 1, 10 μM) rapresented  in terms of growth 
percentage (growth %). 
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Autophagy evaluation through the transfection assay 
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The evaluation of gene expression shows the activation of genes involved in DNA 
damage response and in cell surviving or death pathways, like apoptosis or autophagy 
(fig. 32a- b).  
 
Gene 
MCF7 
ΔΔCt (1 μM) ΔΔCt (5 μM) 
ATM -4,86 -2,10 
ATR 0,83 -3,04 
LC3 -1,56 -1,53 
Beclin1 -2,99 -2,43 
mTOR -1,82 -1,44 
 
Table 4: mRNA expression of genes involved in DNA damage response and in autophagy 
in K562 cell line and in C-MSCs cell line after 0.5- 1 μM Doxorubicin treatment.  
ΔΔCt values = ΔCt of treated − ΔCt of control;  ΔCt = (Ct of sample − Ct ActB) 
 
  
 Figure 32: evaluation of expression of genes involved 
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C-MSCs cell line: 
Doxorubicin (1, 5, 50 μM) treatment induces a reduction of cell number in culture in C-
MSCs cell line in a dose and time dependent manner (fig. 33). As in MCF7 cell line also in 
C-MSCs cell line is observable genotoxicity induction after Doxorubicin (1, 10, 100 μM) 
treatment  (p<0.001) (fig. 34). 
 
 
 
 
Figure 33: Cytotoxicity (MTS assay) induced on C-MSCs cell line after  24 and 48 h 
treatment with  doxorubicin (0.1, 0.5, 1, 10, 50 μM) represented in terms of growth 
percentage (growth %). 
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Figure 34:  Genotoxicity (Comet assay) in C-MSCs cell line after 4 and 24 h treatment 
with  doxorubicin (1, 10, 100 μM) evaluated in terms of percentage of DNA in comet tail 
(tail intensity : TI%); NT= untreated 
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Discussion and Conclusions 
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Imatinib mesylate, inhibitor of specific tyrosine kinases like BCR-ABL and c-kit, has 
revolutionized treatment of chronic myeloid leukemia and gastro- intestinal stromal 
tumors patients. IM and other drugs belonging to the family of targeted therapies have 
changed our thinking about cancer, which can now be viewed as a group of diseases 
that, even if not curable, can be managed for years, similar to many other chronic 
diseases. 
Despite of its high selectivity, side effects have been found in non- target tissues. In 
particular IM treatment seems to be related with adverse effects on cardiovascular 
system. 
Objective of this thesis was to analyze in vitro response of different cellular types to IM 
treatment. Since IM side effects could be due not only to damages in terminally 
differentiated cells [Kerkela R, et al. 2006] but also to a pauperization of cardiac stem 
cells, I have used for my study two cardiac stem cell lines, rat cardiac progenitor cells 
(CPCs) and human cardiac mesenchimal stem cells (C-MSCs). Furthermore a chronic 
myeloid leukemia cell line (K562) expressing the specific target protein BCR-ABL has 
been used as positive control. Different endpoints indicating the presence of a cellular 
stress have been evaluated: cytotoxicity through MTS assay, genotoxicity through 
alkaline Comet assay, reactive oxygen species (ROS) production through a fluorescent 
assay, autophagy activation through a transfection assay, and changes in gene 
expression were evaluated by quantitative RT-PCR. 
Two different concentrations of IM have been used to evaluate the toxicity induced by 
treatments: 5 μM comparable with plasmatic drug dose in patients after in vivo 
treatment; 50 μM to induce a response that mimic drug accumulation due to a 
prolonged treatment. 
As expected IM treatment, with both the tested doses, induces an high cytotoxicity in 
the target cell line K562 (fig. 16). An high cytotoxicity is detectable at 50µM in both 
cardiac cell lines (fig. 17a- b); while at 5µM, rat CPCs show a mild growth inhibition (fig. 
17a) and human C-MSCs show a proliferation rate comparable to the untreated cells 
rate (fig. 17b). Even if lower than in target cell line, cytotoxicity observed in cardiac stem 
cells can’t be explained by the inhibition of tyrosine kinase BCR- ABL, IM primary action; 
suggesting that the adverse effects of IM could be due to inhibition of aspecific tyrosine 
kinase. It is known that IM can interact, even if with minor affinity, with other proteins 
like c-kit that is fundamental for cardiac stem cells (CSC) and cardiac resident stem cells 
(CRSC) differentiation in cardiomyocytes and for CSC migration from bone marrow to 
hearth. Alterations in stem cell migration and maturation could prejudice their 
capability to replace damaged tissue and repair lesions [Ayach et al., 2006; Cheng e 
Force, 2010]. 
68 
 
The high cytotoxicity levels led me to investigate cell death pathway involved. The first 
studies of adverse IM effects on cardiac tissues underlined a reduction of left ventricle 
mass not associated with an increase of apoptosis levels; furthermore they have 
observed the lack of fibrotic area meaning the absence of necrotic cell death [Kerkela et 
al., 2006; Leipner et al., 2008; Terabe et al., 2009]. These assumptions led me to 
investigate alternative cell death pathways, like autophagy. In the last year it is 
emerging the fundamental role of autophagic pathway in cardiac tissue for its capacity 
to eliminate damaged cell material or the entire cell. Our data seem to confirm the 
intervention of this cell pathway in response to IM treatment with both tested 
concentrations (fig. 21, 22a- b ). Interestingly autophagy basal levels in cardiac cells are 
higher than in K562, meaning that autophagy could have an important function in cells 
committed to cardiac compartment (fig. 22a- b ). Autophagy activation has been 
confirmed through quantitative RT- PCR that shows induction of genes involved in 
autophagic pathway like LC3, Beclin1, mTOR and Bcl2. Investigations performed through 
Alkaline version of Comet Assay show the induction of an increment of DNA migration 
after IM treatment in all cell lines tested; in particular K562 treatment with both IM 
concentrations induces a significant genotoxicity during the early times of treatment 
that seems to decrease over time. The reduction of genotoxicity could be due to repair 
of initial DNA damage or most likely to death of damaged cells (as confirmed also by 
cytotoxicity data) (fig. 18) and the consequent selection of a resistant population. 5 μM 
IM seems to induce a lower damage in cardiac stem cells than in K562, and this damage 
disappears after 24h treatment. On the other hand the higher dose induces in these cell 
lines an acute genotoxicity that increases over time. 
DNA damage can induces a series of cellular response to face insult: the first step is the 
activation of damage checkpoints, cell cycle arrest and induction of repair machinery 
and as last chance cell death pathways are activated to eliminate highly damaged cells; 
every cellular events is associated with modifications in transcriptome and proteome 
profile [Rodriguez-Rocha et al., 2011]. 
The presence of DNA damage is confirmed also through quantitative real time PCR (RT-
PCR) that shows the activation of transcription of genes that encoding ATM and ATR, 
 two kinases which are activated by DNA double-strand breaks (DSBs) and single-
stranded DNA respectively. These proteins are able to induce a cell cycle arrest to allow 
DNA damage repair [Smith et al. 2010]. IM treatment induces the contemporary 
induction of ATM and ATR in K562 cell line, in c-MSCs cell line only ATR is expressed; this 
differential transcription of genes involved in DNA damage response could indicate the 
induction of a different kind of damage in cells after treatment. Recent studies have 
shown that the induction of ATM transcription could occur not only in presence of DNA 
damage but also as result of a direct inhibition of ATM kinase; Khalil and collaborators 
69 
 
have demonstrated that pharmacological inhibition of ATM protein induces an 
autoregulatory induction of ATM transcription [Khalil et al. 2012]. 
The Induction of genotoxicity from a molecule that acts as tyrosine kinase inhibitor was 
totally unexpected, but the presence of DNA fragmentation already after few hours of 
treatment led me to speculate about and to confirm the induction of oxidative damage 
as suggested by Czechowska and collaborators (2005). In their study they have detected 
the induction of DNA damage on K562 cell line after IM treatment; the use of a modified 
version of comet assay, which involves the use of endonuclease III (enzyme with 
glycosilase an liase activity during the early phases of Base Excision Repair (BER) that 
allows to detect the presence of oxidized bases), showed an increase of DNA migration, 
meaning the presence of oxidative damage [Czechowska et al., 2005]. The evaluation of 
Reactive Oxygen Species (ROS) that I have performed through a fluorescent assay shows 
a relevant induction of oxidative stress confirming this hypothesis. Interestingly cardiac 
stem cells seem to have an higher resistance against oxidative stress as shown by the 
different impact of Menadione (molecule that is known to induce production of reactive 
oxygen species [Bladen et al., 2012]) on this cell line than on K562 cell line. 
Recent studies have demonstrated a link between DNA damage and autophagy 
activation [Rodriguez-Rocha et al., 2011]. Data reported in this thesis seem to confirm 
this hypothesis: a contemporary induction of these two cell responses are detectable 
after IM treatment (fig. 35a- b). 
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Figure 35: Comparison of autophagic and genotoxic levels in CPCs (a) and C-MSCs (b) 
after IM treatment; IM= Imatinib mesylate; TI= tail intensity %; AF= cells with active 
autophagic pathaway. 
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The growing evidence of the importance that autophagy could have in cellular response 
to  chemotherapy, as pro-survival or pro-death mechanism, led me to deepen the role 
of autophagy in IM treatment. Furthermore to find a possible link between autophagy 
and cytotoxic and genotoxic effects, co- treatments with autophagy regulators 
(chloroquine as autophagy inhibitor or lithium chloride as autophagy inducer) have been 
conducted. Co- treatments with IM 5 μM and autophagy regulators were performed; 
CQ/HCQ (autophagy inhibitor) and lithium chloride (autophagy inducer) are drugs used 
for many years in treatment of human diseases, so their absorption kinetics and 
collateral effects are known. This aspect drives me to use these two molecules during 
my study. 
The inhibition of autophagy in K562 cell line induces an increase of cytotoxicity observed 
after IM treatment; on the other hand autophagy activation favors cell surviving (fig. 
25), confirming the role of autophagy as resistance  machinery in chemotherapy 
[Salomoni P, et al. 2009]. In both cardiac cell lines autophagy modulation with inducer 
or inhibitor produces an arrest of cell proliferation (fig. 26a- b). This behavior suggests 
that autophagy is strongly regulated and every variation could compromise cell 
response to drug treatment. As in all finally differentiated cells, autophagy has a primary 
role in cardiac cells. In non dividing cardiac cells cellular wastes can’t be redistributed in 
daughter cells and a reduction of autophagy levels induces a organelles/proteins 
accumulation that contributes to induce cardiac diseases. Moreover cardiomyocytes are 
long life cells and for this reason they are susceptible to aging that can hit cellular 
structures like mitochondria and lysosomes, in this contest autophagy represents a key 
pathway to allow a rapid turn-over of cellular components. It is known that cardiac cells 
use autophagic pathway as mechanism needful to cell homeostasis maintenance during 
condition of pharmacological stress too [Martinet W, et al. 2007]. Comet assays have 
been performed after autophagy inhibition in human cell lines (K562 and C-MSCs) to 
evaluate DNA damage variation. In K562 cell line a decrease in DNA damage is observed 
after autophagy inhibition. This behavior is probably due to death of damaged cells and 
to the selection of resistant cells as confirmed through cytotoxicity data obtained 
through MTS assay (fig. 25) . In C-MSCs cell lines a reduction of DNA migration is evident 
after autophagy inhibition; interestingly the highest DNA damage reduction coincides 
with the autophagy peak observed in these cells after IM treatment (fig. 36). 
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Figure 36: Comparison of autophagic and genotoxic levels in C-MSCs after IM treatment 
with or without chloroquine; IM= Imatinib mesylate; IM + CQ= IM- chloroquine  co-
treatments; TI= tail intensity %. 
 
This observation could confirm autophagy intervention in DNA damage repair. Also gene 
expression analysis confirm the co-expression of this two cell events, a contemporary 
expression of genes involved in authophagic pathway (LC3 e Beclin1) and enzymes that 
have a role in DNA damage surveillance (ATM and ATR) is observed (fig. 37). Robert and 
collaborators have demonstrated the involvement of autophagy in degradation of 
components that takes part in DNA repair. This degradation through autophagy seems 
to depend on post-translational modifications as acetylation, modification that has been 
observed in many enzymes involved in repair systems [Robert T, et al. 2011]. 
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Figure 37: gene expression of ATR and autophagic genes LC3 and
mesenchimal stem cell (C-MSCs) after IM treatment
 
 
Ultimately, a comparison between Imatinib mesylate and Doxorubicin, as old generation 
chemotherapic with known cardiotoxic activity, has been conducted. With both drugs 
used toxicity has been observed in C
particular  Doxorubicin seems to
damage induction, in a comparable manner in both target cell line, MCF
target cell line, C-MSCs. Conversely IM induce
different cell lines. An high toxicity is observable in target cell line, K562 with all the 
tested doses; conversely in C-
with the higher dose. These observation
respect to Doxorubicin. 
Data reported in this thesis show how treatment with IM could imply a complex cellular 
response not only in target cell lines but
genotoxicity, oxidative stress and autophagy activation have been observed in all cell 
lines tested. The higher effects in cardiac stem cell lines are detectable after acute 
treatment, but these data have 
with the highest IM dose may occur 
cardiac compartment after prolonged treatment.
Furthermore autophagy seems to represent  in K562 
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reduction in cell viability. Interestingly the use of chloroquine as autophagy inhibitor 
during IM treatment seems to reduce toxicity observed in cardiac stem cell lines. For 
this reason autophagy inhibition through chloroquine could represent a good approach 
in the development of  new combined antitumor therapies able to decrease toxicity 
induced in non- target cell lines without affecting the drug efficacy. 
  
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
 
  
76 
 
Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, Inoki K, Guan K, Shen J, 
Person MD, Kusewitt D,  Mills GB, Kastan MB, Walker CL. ATM signals to TSC2 in the 
cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 2010. 
107:4153–4158 
Axe EL, Walker SA, Manifava M, Chandra P, Roderick HL, Habermann A, Griffiths G, 
Ktistakis NT. Autophagosome formation from membrane compartments enriched in 
phosphatidylinositol3-phosphate and dynamically connected to the endoplasmic 
reticulum. J Cell Biol. 2008.  Aug 25;182(4):685-701 
Ayach BB, Yoshimitsu M, Dawood F, Sun M, Arab S, Chen M, Higuchi K, Siatskas C, Lee P, 
Lim H, Zhang J, Cukerman E, Stanford WL, Medin JA, Liu PP. Stem cell factor receptor 
induces progenitor and natural killer cell-mediated cardiac survival and repair after 
myocardial infarction. Proc Natl Acad Sci U S A. 2006 Feb 14; 103 (7) :2304-9.  
Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, 
Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse 
U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G. Quantitative chemical 
proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat 
Biotechnol. 2007;25:1035–1044. 
Bladen CL, Kozlowski DJ, Dynan WS. Effects of low-dose ionizing radiation 
and menadione, an inducer of oxidative stress, alone and in combination in a vertebrate 
embryo model. Radiat Res. 2012 Nov;178(5):499-503. 
Bland EJ, Keshavarz T, Bucke C. Using 2', 7'-Dichlorodihydrofluorescein-diacetate to 
Assess Polysaccharides as Immunomodulating Agents. Mol. Biotec. 2001. Vol. 19: 125-
31. 
Blasiak J, Gloc E, Pertyński T, Drzewoski J. DNA damage and repair in BCR/ABL-
expressing cells after combined action of idarubicin, STI571 and amifostine. Anticancer 
Drugs. 2002 Nov;13(10):1055-60. 
Cadeddu C. Effetti cardiotossici precoci e tardivi del  trattamento con Epirubicina. 
Valutazione con marker biochimici ed ecocardiografia Tissue Doppler PhD thesis 2006-
2007 
Cattley RC, Radinsky RR. Cancer therapeutics: understanding the mechanism of action. 
Toxicol Pathol. 2004 Mar-Apr; 32 Suppl 1:116-21.  
77 
 
Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces 
autophagic cell death independent of apoptosis in transformed and cancer cells. Cell 
Death Differ. 2008 Jan; 15 (1) :171-82.  
Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer 
therapeutics. Circ Res 2010;106: 21-34. 
Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell 
Cycle 2010. 9:6, 1091-1096 
Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, 
Daher IN, Pati S, Patel SS, Pocius JS, Taffet GE, Buja LM, Entman ML, Khakoo AY. 
Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac 
response to load-induced stress. J Clin Invest. 2010 Feb 1; 120 (2) :472-84. 
Cuervo AM. Chaperone-mediated autophagy: selectivity pays off. Trends Endocrinol 
Metab. 2009 Mar;21(3):142-50.  
Dalzell JR, Samuel LM. The spectrum of 5-fluorouracil cardiotoxicity. Anticancer Drugs. 
2009 Jan; 20 (1) :79-80.  
De Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development 
and treatment response. Cancer Treat Rev. 2008 Dec; 34 (8) :737-49.  
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, 
Gélinas C, Fan Y, Nelson DA, Jin S, White E. Autophagy promotes tumor cell survival and 
restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006. 10:51–64. 
Ding WX, Ni HM, Gao W, Hou YF, Melan MA, Chen X, Stolz DB, Shao ZM, Yin XM. 
Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J 
Biol Chem. 2007 Feb 16; 282 (7) :4702-10.  
Fujita N, Hayashi-Nishino M, Fukumoto H, Omori H, Yamamoto A, Noda T, Yoshimori T. 
An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in 
autophagosome closure. Mol Biol Cell. 2008 Nov;19(11):4651-9 
Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced 
cardiotoxicity: review of the literature. Anticancer Drugs. 2010 Jul; 21 (6) :578-90.  
78 
 
González-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquère S, Eskelinen EL, 
Pierron G, Saftig P, Kroemer G. The apoptosis/autophagy paradox: autophagic 
vacuolization before apoptotic death. J Cell Sci. 2005 Jul 15; 118 (Pt 14) :3091-102.  
Grune T, Merker K, Jung T, Sitte N, Davies KJ. Protein oxidation and degradation during 
postmitotic senescence. Free Radic Biol Med. 2005 Nov 1; 39 (9) :1208-15. 
Guillon-Munos A, van Bemmelen MX, Clarke PG. Role of phosphoinositide 3-kinase in 
the autophagic death of serum-deprived PC12 cells. Apoptosis. 2005 Oct; 10 (5) :1031-
41.  
Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, Reynoso D, McMahon J, Taguchi T, 
Floris G, Debiec-Rychter M, Schoffski P, Trent J.A, Debnath J, Rubin BP. Autophagy 
inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). 
Proc Natl Acad Sci USA 2010 Aug10;107 (32):14333-8. 
Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007; 446:145–146 
Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart 
by preconditioning. Biochim Biophys Acta  2007; 1767: 1007–1031. 
Jahreiss L, Menzies, FM, and Rubinsztein, DC. The itinerary of autophagosomes: from 
peripheral formation to kiss and-run fusion with lysosomes. Traffic 2008 9; 574–587. 
Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 
2000; 7:53–62. 
Jones SE, Savin MA, Holmes FA. Phase III trial comparing doxorubicin plus 
cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for 
operable breast cancer. J. Clin. Oncol., 2006, 24, 5381. 
Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, Kundu M, Kim DH. ULK-Atg13-FIP200 
complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009 
Apr; 20 (7):1992-2003 
Jung HS, Chung KW, Won Kim J, Kim J, Komatsu M, Tanaka K, Nguyen YH, Kang TM, Yoon 
KH, Kim JW, Jeong YT, Han MS, Lee MK, Kim KW, Shin J, Lee MS. Loss of autophagy 
diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell 
Metab 2008, 8:318-324 
79 
 
Khalil HS, Tummala H, Hupp TR, Zhelev N. Pharmacological inhibition of ATM by 
KU55933 stimulates ATM transcription. Exp Biol Med (Maywood). 2012 Jun;237(6):622-
34. 
Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and 
apoptosis. Cell Death Differ. 2011 Apr;18(4):571-80 
Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and 
apoptosis. Cell Death Differ. 2011 Apr;18(4):571-80 
Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G,Mathew R, Jin S, White E. 
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. 
Genes Dev 2007. 21:1621–1635. 
Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G,Mathew R, Jin S, White E. 
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. 
Genes Dev 2007. 21:1621–1635. 
Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin 
Invest. 2002 Nov; 110 (10) :1389-98.  
Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, 
Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force 
T. Cardiotoxicity of the cancer therapeutic agent IM . Nat Med. 2006 Aug; 12 (8) :908-16.  
Kimura S, Noda T, Yoshimori T. Dynein-dependent movement of autophagosomes 
mediates efficient encounters with lysosomes. Cell Struct Funct 2008. 33, 109–122. 
Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi 
Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T. Impairment of starvation-induced and 
constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005, 169:425-434. 
Kroemer G, Jäättelä M. Lysosome and autophagy in cell death control. Nat Rev Cancer. 
2005 Nov;5(11):886-97. 
Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response.  Mol 
Cell. 2010 Oct 22;40(2):280-93. 
Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, YoshimoriT, Ohsumi Y, Tokuhisa 
T, Mizushima N. The role of autophagy during the early neonatal starvation period. 
Nature 2004. 432:1032–1036. 
80 
 
Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H, Berndt A, Janik T, Uecker 
A, Kiehntopf M, Böhmer FD. IM  attenuates fibrosis in coxsackievirus b3-induced chronic 
myocarditis. Cardiovasc Res. 2008 Jul 1; 79 (1) :118-26.  
Levine B, Yuan J. Autophagy in cell death: an innocent convict?. J Clin Invest. 2005 Oct; 
115 (10) :2679-88.  
Li M, Naqvi N, Yahiro E, Liu K, Powell PC, Bradley WE, Martin DI, Graham RM, Dell'Italia 
LJ, Husain A. c-kit is required for cardiomyocyte terminal differentiation. Circ Res. 2008 
Mar 28; 102 (6) :677-85.  
Li W, Yang Q, Mao Z. Chaperone-mediated autophagy: machinery, regulation and 
biological consequences. Cell Mol Life Sci. 2011 Mar;68(5):749-63. 
Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces 
autophagy in cancer cells by down-regulating HIF-1alpha and Bcl-2 and activating the 
beclin 1/hVps34 complex. Cancer Res. 2010 Jul 15;70(14):5942-52. 
Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction 
of autophagy and inhibition of tumorigenesis by Beclin1. Nature 1999. 402:672–676. 
Lloyd JB. Metabolite efflux and influx across the lysosome membrane. Subcell Biochem 
1996. 27, 361–386. 
Loos B, Lochner A, Engelbrecht AM. Autophagy in heart disease: A strong hypothesis for 
an untouched metabolic reserve. Medical Hypotheses 2011. 77 52–57. 
Lorin S, Borges A, Ribeiro Dos Santos L, Souquère S, Pierron G, Ryan K.M, Codogno P, 
Djavaheri-Mergny M. c-Jun NH2-terminal kinase activation is essential for DRAM-
dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated Ewing 
sarcoma cells.Cancer Res 2009. 69: 6924–6931. 
Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. 
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl 
Acad Sci U S A. 2008 Dec 2; 105 (48) :18895-900.  
Majmundar AJ, Wong WJ, Simon CM. Hypoxia inducible factors and the response to 
hypoxic stress. Mol Cell. 2010; 40 (2):294-309. 
Mariño G, Madeo F, Kroemer G. Autophagy for tissue homeostasis and neuroprotection. 
Current Opinion in Cell Biology 2011, 23:198–206. 
81 
 
Mariño G, Salvador-Montoliu N, Fueyo A, Knecht E, Mizushima N, Lopez-Otin C. Tissue-
specific autophagy alterations and increased tumorigenesis in mice deficient in 
Atg4C/autophagin-3. J Biol Chem 2007. 282: 18573–18583. 
Martinet W, Knaapen MWM, Kockx MM, DeMeyer GRY. Autophagy in cardiovascular 
disease. Trends in Molecular Medicine 2007.13(11):482-91. 
Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, 
Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg 
N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. The autophagic tumor stroma 
model of cancer or “battery-operated tumor growth”. A simple solution to the 
autophagic paradox. Cell Cycle 2010. 9, (21); 4297-4306. 
Massey AC, Zhang C, Cuervo AM. Chaperone-mediated autophagy in aging and disease. 
Curr Top Dev Biol. 2006; 73:205-35. 
Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY,Bray K, Reddy A, Bhanot G, 
Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses 
tumorigenesis through elimination of p62. Cell 2009. 137: 1062–1075. 
Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White 
E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes 
Dev 2007. 21:1367–1381. 
Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, Maejima I, Shirahama-
Noda K, Ichimura T, Isobe T, Akira S, Noda T, Yoshimori T. Two Beclin 1-binding proteins, 
Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol. 
2009 Apr;11(4):385-96. 
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Antrayclines: molecular advances 
and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. 
Rev., 2004, 56, 185. 
Muñoz-Gàmez JA, Rodrìguez-Vargas JM, Quiles-Pérez R, Aguilar-Quesada R, Martìn-
Oliva D, de Murcia G, Menissier de Murcia J, Almendros A, Ruiz de Almodòvar M, Oliver 
F.J. PARP-1 is involved in autophagy induced by DNA damage.  Autophagy 2009. 5; 61–
74. 
Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, 
Matsumura Y, Asahi M, Nishida K, Hori M, Mizushima N, Otsu K. The role of autophagy 
82 
 
in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 
2007.13: 619–624. 
Nakamura N, Matsuura, A, Wada, Y, and Ohsumi, Y. Acidification of vacuoles is required 
for autophagic degradation in the yeast, Saccharomyces cerevisiae. J Biochem 1997 121, 
338–344. 
Nakatogawa H, Ichimura Y, Ohsumi Y. Atg8, a ubiquitin-like protein required for 
autophagosome formation, mediates membrane tethering and hemifusion. Cell. 2007 
Jul 13;130(1):165-78. 
Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. 
Cell Death Differ. 2009 Jan; 16 (1) :31-8. 
O’Donovan TR, O’Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant 
esophageal cancer cells promotes their survival and recovery following treatment with 
chemotherapeutics. Autophagy 2011. 7(5): 509–524. 
Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-
induced cardiomyopathy: From molecular mechanisms to therapeutic strategies Journal 
of Molecular and Cellular Cardiology Volume 52, Issue 6, June 2012, Pages 1213–1225. 
Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, 
Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, 
Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA. Structures 
of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase 
inhibition. Nat Struct Mol Biol. 2004;11:1192–1197. 
Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol 
Cell Biol. 2001 Mar;2(3):211-6. 
Okram B, Nagle A, Adrian FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon 
G, Warmuth M, Liu Y, Gray NS. A general strategy for creating “inactive-conformation” 
abl inhibitors. Chem Biol. 2006;13:779 –786. 
Orenstein SJ, Cuervo AM. Chaperone-mediated autophagy: Molecular mechanisms and 
physiological relevance. Seminars in Cell & Developmental Biology 2010. 21(7):719–726. 
Review. 
83 
 
Pankiv S, Alemu E.A, Brech A, Bruun JA, Lamark T, Overvatn A, Bjørkøy G, Johansen T. 
FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end 
directed vesicle transport. J Cell Biol. 2010 188(2):253–269. 
Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger P.A, Small S, Spencer B, 
Rockenstein E, Levine B, Wyss-Coray T. The autophagy-related protein beclin1 shows 
reduced expression in early Alzheimer disease and regulates amyloid beta accumulation 
in mice. J Clin Invest 2008.118(6): 2190–2199. 
Prezioso L, Tanzi S, Galaverna F, Frati C, Testa B, Savi M, Graiani G, Lagrasta C, Cavalli S, 
Galati S, Madeddu D, Lodi Rizzini E, Ferraro F, Musso E, Stilli D, Urbanek K, Piegari E, De 
Angelis A, Maseri A, Rossi F, Quaini E, Quaini F. Cancer Treatment-Induced 
Cardiotoxicity: a Cardiac Stem Cell Disease? Cardiovascular & Hematological Agents in 
Medicinal Chemistry, 2010, 8, 55-75. 
Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010 Dec 3; 330 (6009) 
:1344-8. 
Raschi E, De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging 
issues in the era of cardio-oncology Intern Emerg Med (2012) 7:113–131. 
Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, O'Kane CJ, Brown SD, 
Rubinsztein DC. Dynein mutations impair autophagic clearance of aggregate-prone 
proteins. Nat Genet 2005. 37(7), 771–776. 
Ravikumar B, Sarkar S, Davies J.E, Futter M, Garcia-Arencibia M, Green-Thompson ZW, 
Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, Massey DC, Menzies FM, 
Moreau K, Narayanan U, Renna M, Siddiqi FH, Underwood BR, Winslow AR, Rubinsztein 
DC.  Regulation of mammalian autophagy in physiology and pathophysiology.  Physiol 
Rev. 2010; 90(4):1383-435. 
Reef S, Zalckvar E, Shifman O, Bialik S, Sabanay H, Oren M, Kimchi A. A short 
mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. 
Mol Cell. 2006 May 19; 22 (4) :463-75. 
Rioux JD,  Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, 
Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, 
Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, 
Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for 
Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007 39(5): 
596–604. 
84 
 
Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, Botrugno OA, 
Parazzoli D, Oldani A, Minucci S, Foiani M. HDACs link the DNA damage response, 
processing of double-strand breaks and autophagy. Nature 2011. 471(7336):74-9. 
Rodriguez-Rocha H, Garcia-Garcia A, Panayiotidis M.I, Franco R. DNA damage and 
autophagy.  Mutation Research 2011. 711(1-2):158–166. 
Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest. 
2002 Nov; 110 (10) :1383-8.  
Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers 
T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky M, 
Wouters BG. The unfolded protein response protects human tumor cells during hypoxia 
through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010 Jan 
4; 120 (1) :127-41.  
Roy S, Debnath J. Autophagy and Tumorigenesis. Semin. Immunopathol 2010. 
32(4):383–396. 
Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin 
cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 
1998; 16:3502–3508. 
Sadasivan S, Waghray A, Larner SF, Dunn WA Jr, Hayes RL, Wang KK. Amino acid 
starvation induced autophagic cell death in PC-12 cells: evidence for activation of 
caspase-3 but not calpain-1. Apoptosis. 2006 Sep; 11 (9) :1573-82.  
Saftig P, Beertsen W, Eskelinen EL. LAMP-2: a control step for phagosome and 
autophagosome maturation. Autophagy 2008. 4, 510–512. 
Sagné C, Agulhon C, Ravassard P, Darmon M, Hamon M, El Mestikawy S, Gasnier B, Giros 
B. Identification and characterization of a lysosomal transporter for small neutral amino 
acids. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7206-11. 
Salomoni P, Calabretta B. Targeted therapies and autophagy: new insights from chronic 
myeloid leukemia. Autophagy. 2009 Oct;5(7):1050-1. 
Sarkar S, Rubinzstein DC. Inositol and IP3 Levels Regulate Autophagy. Autophagy 2006. 
2(2):132-134. 
85 
 
Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, Ueno T, Ochiai A, Esumi H. 
Autophagy is activated in colorectal cancer cells and contributes to the tolerance to 
nutrient deprivation. Cancer Res 2007. 67(20): 9677–9684. 
Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic 
drugs. Cancer Treat Rev 2004; 30:181–191. 
Schwab M, Klempnauer KH, Alitalo K, Varmus H, Bishop M. Rearrangement at the 5end 
of amplified c-myc in human COLO 320 cells is associated with abnormal transcription. 
Mol Cell Biol. 1986;6: 2752–2755. 
Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J 
Clin Invest. 2007;117:2067–2074. 
Shibata M, Lu T, Furuya T, Degterev A, Mizushima N, Yoshimori T, MacDonald M, 
Yankner B, Yuan J. Regulation of intracellular accumulation of mutant Huntingtin by 
Beclin 1. J Biol Chem. 2006 May 19; 281 (20) :14474-85.  
Simonsen A, Tooze S.A. Coordination of membrane events during autophagy by multiple 
class III PI3-kinase complexes. J Cell Biol. 2009 Sep 21;186(6):773-82. 
Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA 
damage signaling and cancer. Adv Cancer Res. 2010;108:73-112. 
Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature. 
2006 Jun 29; 441 (7097) :1097-9. 
Sun Q, Fan W, Chen K, Ding X, Chen S, Zhong Q. Identification of Barkor as a mammalian 
autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc 
Natl Acad Sci U S A. 2008; 105(49):19211-6. 
Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M, 
Cecconi F, Tavernarakis N, Kroemer G. A dual role of p53 in the control of autophagy. 
Autophagy. 2008; 4(6); 810-814 
Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, Modjtahedi N, Kroemer 
G. Methods for Assessing Autophagy and Autophagic Cell Death. Methods Mol 
Biol. 2008;445:29-76. 
Terabe F, Kitano M, Kawai M, Kuwahara Y, Hirano T, Arimitsu J, Hagihara K, Shima 
Y, Narazaki M, Tanaka T, Kawase I, Sano H, Ogata A. Imatinib mesylate inhibited rat 
86 
 
adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference 
with the Akt signaling pathway. Mod Rheumatol. 2009;19(5):522-9. 
Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of 
postmitotic aging and cell death. Chem Biol Interact. 2006 Oct 27; 163 (1-2) :29-37. 
Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, 
Molina TJ, Gisselbrecht C, Reyes F, Groupe d'Etude des Lymphomes de l'Adulte. 
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP 
for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 2003, 102, 4284. 
Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell 
Death Differ. 2005 Nov; 12 Suppl 2:1528-34. 
Uttenweiler A, Schwarz H, Mayer A. Microautophagic vacuole invagination requires 
calmodulin in a Ca2+-independent function. J Biol Chem. 2005 Sep 30; 280 (39) :33289-
97.  
Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kögel D. The pan-
Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol 
Cancer Res 2010.  8(7):1002–1016. 
Wong CH, Iskandar KB, Yadav SK, Hirpara JL, Loh T, Pervaiz S. Simultaneous induction of 
non canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK 
activation. PLoS One. 2010; 5(4):e9996. 
Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FKL, Yu J, Sung JJ. The autophagic 
paradox in cancer therapy. Oncogene 2011. 1–15. 
Xilouri M, Stefanis L. Autophagic pathways in Parkinson disease and related disorders. 
Expert Rev Mol Med. 2011 Mar 21; 13:e8.  
Yang Z,  Klionsky J.  Eaten alive: a history of macroautophagy . Nat Cell Biol. 2010 
Sep;12(9):814-22. 
Yang Z, Huang J, Geng J, Nair U, and Klionsky DJ. Atg22 recycles amino acids to link the 
degradative and recycling functions of autophagy. Mol Biol Cell 2006. 17, 5094–5104. 
Yang ZJ, Chee CE, Huang S, Sinicrope FA. The Role of Autophagy in Cancer: Therapeutic 
Implications. Mol Cancer Ther 2011. 10(9):1533-1541. 
87 
 
Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon 
HU. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 
2006. 8(10), 1124–1132. 
Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-Xl play important roles in the crosstalk between 
autophagy and apoptosis. FEBS J. 2011 Feb;278(3):403-13. 
Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field 
LJ. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the 
mTOR pathway. Circulation. 2009 January 6; 119(1):99–106. 
  
88 
 
Ringraziamenti 
Arrivata alla fine di questo percorso voglio ringraziare tutti coloro che mi hanno 
permesso di svolgere il mio lavoro di dottorato. Ringrazio il coordinatore del dottorato 
di ricerca in Fisiopatologia Sistemica, Professore Enrico Maria Silini; i Professori Federico 
Quaini, Annamaria Buschini e Carlo Rossi per avermi guidata durante la mia ricerca 
scientifica e per avermi sostenuta con la loro professionalità e la loro disponibilità.  
Ringrazio inoltre tutti i miei colleghi di laboratorio: Francesca, Francesco, Alessio e 
Valeria. Un ringraziamento particolare a Mirca Lazzaretti per il supporto tecnico- 
scientifico.  
Grazie anche a tutti i ragazzi che mi hanno aiutato durante la mia ricerca: Alessio, 
Andrea, Claudia e Carla e a tutti i tesisti triennali che hanno contribuito al lavoro.  
Ringrazio Roberto Silva e  Antonietta Cirasolo per il loro supporto tecnico. 
In ultimo ringrazio la mia famiglia e Walter per il loro insostituibile affetto e supporto 
quotidiano. 
 
